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Abstract 
 
(2R)-N-Benzyl-2-acetamido-3-methoxypropionamide (lacosamide) is an 
anticonvulsant (Choi et al., 1996); under the brand name “Vimpat” this small molecule has 
recently been approved by the European Medicines Agency and the U.S. Food and Drug 
Administration for the treatment of epilepsy.  The purpose of the research reported here is to 
develop and apply mass spectrometry approaches to the determination of protein targets of 
this novel therapeutic.  
The general strategy involves selecting potential target proteins using lacosamide 
analogues incorporating an ‘affinity bait’ to enable covalent modification binding to target 
proteins, and a ‘chemical reporter’ for the selective recovery of modified proteins. 
Lacosamide analogues are incubated with biological samples (primarily mouse brain 
extracts) and the modified proteins are recovered by introduction of a biotin tag (via the 
chemical reporter group). Streptavidin affinity chromatography is then used to enrich for 
bound molecules. The enriched proteins are subjected to tryptic digestion and the resultant 
peptides analysed by reversed phase liquid chromatography coupled with tandem MS, 
enabling recognition of proteins via database searching 
Firstly, mass spectrometric characterisation of the biotinyl (R)-lacosamide analogue 
bound to model compounds was performed. Adducts with protected lysine, neurotensin and 
enolase were analysed. The data showed that ESI was more suitable for ionisation of 
modified peptides and proteins than MALDI.  The biotin enrichment strategy was applied to 
mouse brain lysate to identify putative candidate target proteins. Twenty-eight candidate 
target proteins were identified. Moreover, the 14-3-3 protein family, CRMP2 and the 
sodium/potassium-transporting ATPase family showed preference for the biologically active 
(R)- isomer over the (S)- lacosamide analogue using a fluorescence tag.  
 Three more biotinyl lacosamide analogues containing different affinity baits were 
used to enrich candidate target proteins of lacosamide. Most of the identified target proteins 
supported the findings of the analogue A. To indicate the binding sites, a method was 
developed for  enriching peptides modified by the biotinyl (R)-lacosamide analogue, using 
streptavidin beads and subsequently analysed these biotinylated peptides using CID and 
ETD fragmentation methods.  Neither fragmentation technique was optimal for elucidation of 
the sequence or site of modification of unknown target peptides. Purified recombinant 
proteins were therefore adducted with an AB-(R)-lacosamide analogue lacking the biotin 
probe. This smaller (R)-lacosamide analogue underwent less fragmentation than the biotin 
analogue during CID and could be used for sequence and site identification of the modified 
peptides. 
In summary, the studies illustrated the power of MS to study drug mechanisms via 
the discovery of candidate protein targets.   
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CHAPTER 1 
Introduction 
1.1  Epilepsy and neuropathic pain 
 
 Epilepsy and neuropathic pain are clusters of neurological disorder symptoms, which 
occur due to the disruption of usual brain activity. Epilepsy describes many types of recurrent 
seizures from an abnormal and excessive discharge of the brain1. Around 50 million people 
worldwide have epilepsy and only 70% of patients respond to current treatments. 
Neuropathic pain is a type of chronic pain which is caused by a disease or injury in the 
nervous system for example from accident, surgery, infection, cancer, diabetic neuropathy 
and others2. A number of studies show that epilepsy and neuropathic pain are similar in 
terms of their pathological symptoms. Therefore, antiepileptic drugs are often able to 
manage neuropathic pain3. Many anticonvulsants are currently available in the market 
worldwide. Unfortunately, the medications are ineffective for approximately one-third of 
patients with epilepsy4. Some patients continue to have seizures, while others experience 
disturbing side effects for example drowsiness, dizziness, nausea and liver damage5. 
Because of these disadvantages, current research focuses on discovering new therapeutic 
agents with novel mechanisms of action. The ability to identify specific nervous system 
pathways and protein target sites responsible for seizures would accelerate the development 
of new and safer therapeutic agents. 
 
1.2  Lacosamide 
 
 In 1985, functionalized amino acids were discovered as a novel class of 
anticonvulsant agents6.  The lead compound was R-2, R-N-benzyl 2-acetamido-3-
methoxypropionamide, also called (R)-lacosamide (Figure 1.1).  Under the brand name 
Vimpat®, (R)-lacosamide was granted market authorisation by the European Commission 
and United States Food and Drug Administration as an adjunctive therapy for partial-onset 
seizures in adults7. 
 
Figure 1.1 Structure of (R)-lacosamide.  
 
Whole animal pharmacological studies have documented that (R)-lacosamide function is 
unique and prevents seizure spread by mechanisms different from those of current clinical 
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agents. Lacosamide was effective against sound-induced seizures in the genetically 
susceptible Frings mouse8. It was also effective against maximal electroshock test (MES)-
induced seizures in rats and mice8.  Radioligand displacement assays using more than 100 
potential binding sites, which include both ligand- and voltage-gated receptors, failed to 
identify high-affinity binding targets9, suggesting that either the target sites are novel or the 
binding is weak or both. Only recently has (R)-lacosamide function been reported to be 
correlated to the modulation of both the slow inactivation gate of sodium channels10 and 
collapsin response mediator protein 29. The full mechanism of pharmacological pathways for 
(R)-lacosamide remains unknown. This research project was therefore designed to identify 
the target protein(s) of (R)-lacosamide using mass spectrometry, a powerful analytic 
technique for protein determination and quantification. 
 
1.3 Proteomics 
 
 DNA contains genetic information11. The DNA sequence is transcribed into a 
complementary RNA sequence. This RNA copy is then used to code for the amino acid 
sequence of proteins in a process called translation. DNA sequence and functional genomics 
have been studied to obtain complete genetic code and understand the human phenotypes. 
The entire human genome was decoded12,13. However, the genetic sequence is not sufficient 
to understand biological function. The study of proteins therefore is of great interest. 
Proteomics, the characterisation of the proteins expressed by the genome of the cell, tissues 
and biological fluids, is not static because of the regulation of gene expression and post-
translational modifications (Figure 1.2). 
 
Figure 1.2 Schematic diagram of the transcription of DNA and translation of RNA. 
 
The major goal of proteomics is to understand the protein complement of cells, including 
their identification, modification, quantification and localization. Several methods are 
currently available to assist these goals and the most common technique for proteomic 
strategies is mass spectrometry (MS)14. MS is now the most sensitive technique for the 
analysis of the proteome, replacing previous methods such as Edman degradation15. Two 
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fundamental strategies of MS-based proteomics strategies are bottom-up and top-down16. In 
the bottom-up approach, proteins or complex protein mixtures are subjected to proteolytic 
cleavage, usually with trypsin and the peptide products are analysed by MS14. In the top-
down approach, intact proteins or large protein fragments are ionized and analysed after 
fragmentation in the gas-phase17. Sample preparation is one of the most crucial processes in 
proteomics research18. The results of the experiment depend on the conditions of the starting 
material. Therefore, the proper experimental model and careful sample preparation is vital to 
obtain significant and trustworthy results. Several suitable protein separation techniques for 
proteomics will be described in this Chapter. 
 
1.4 Separation techniques for proteomics 
 
 To reduce complexity of proteomic samples, many techniques can be used to 
separate complex mixtures. However, there is no standardized strategy for sample 
preparation, protein purification or fractionation. Gel electrophoresis and strong cation 
exchange chromatography are the most common techniques used to separate proteins 
and/or peptides prior to MS. In addition, reversed phase liquid chromatography coupled to 
tandem mass spectrometry offers high performance to separate and detect peptides. 
 
1.4.1 Gel electrophoresis 
 
One-dimensional electrophoresis Most electrophoresis procedures for resolving 
proteins in use today employ polyacrylamide gels. Polyacrylamide gels are formed from the 
polymerization of monomeric acrylamide and the bifunctional cross-linking monomer N,N’-
methylene bisacrylamide. A wide range of pore sizes can be formed by varying the amount 
of total acrylamide used per unit volume and the degree of cross-linkage. As the proportion 
of cross-linker is increased, the pore size decreases.  
By applying an electric field, the protein will move through the gel at different rates, 
toward the positive electrode if the protein is negatively charged. Native forms of proteins 
fold into a variety of shapes. The rate of migration of native proteins through a 
polyacrylamide gels is therefore more a reflection of their relative compactness, and less an 
accurate measure of molecular weight. In sodium dodecyl sulphate (SDS) gel 
electrophoresis, the SDS uniformly surrounds the protein at a ratio of 1.4g SDS per gram of 
protein. All proteins are given negative charges and move towards the positive electrode. 
The migration of proteins is directly related to the size of proteins because their higher 
structures are denatured and uncoiled19.  
Two-dimensional electrophoresis This was described for the first time in 1974 and 
has been used extensively in proteomics20. In the first dimension, the samples are separated 
in an immobilized pH gradient (IPG) strip, which is rehydrated and a subjected to an electric 
potential. The pH gradients are created by carrier ampholytes which distribute over a wide 
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spectrum from pH 3 to 10. The proteins move along the strip and will accumulate at their 
isoelectric point (the pH at which the net charge on the protein is zero). After separation in 
the first dimension, they are separated in the second dimension using traditional one-
dimensional gel electrophoresis.   
Multiple different staining procedures have been developed to visualise proteins 
separated by SDS-PAGE. Colloidal Coomassie is commonly used because it is simple and 
stained gels are compatible with mass spectrometry analysis. It has a detection range of 8-
50 ng of protein within a spot21. Silver staining is highly sensitive and provides superior 
detection, typically 2-4 ng of protein per spot22. Several silver staining protocols have been 
developed which offer improved compatibility with subsequent mass spectrometric 
analysis23. Finally, fluorescent stains provide sensitivity similar to silver stain but without the 
complex methodology and the problems with mass spectrometric compatibility. However, 
they are very expensive and require fluorescent scanners for analysis24.  
 
1.4.2 Strong cation exchange chromatography 
Ion exchange chromatography is divided into four types categorised by their ionic 
stationary phase biopolymers: (i) strong anion exchanging groups consisting of aliphatic 
quaternary amines, (ii) weak anion exchanging groups consisting of primary, secondary, or 
tertiary amines, (iii) a strong cation exchanging sulfonic acid group, and (iv) a weak cation 
exchanging carboxyl group25. Strong ion exchangers are always ionized. They are typically 
used to retain and separate weak analytes such as peptides and proteins. These weak 
analytes may be eluted by displacement with a mobile phase containing ions that are more 
strongly attracted to the stationary phase sites. Alternately, weak ions may be eluted by 
changing the pH of the mobile phase, causing them to lose their attraction and elute. Weak 
ion exchangers may be neutralized or charged. When charged, they are used to retain and 
separate strong analytes such as inorganic ions. If these ions cannot be eluted by 
displacement, then the stationary phase exchange sites may be neutralized, shutting off the 
ionic attraction, and permitting elution of the charged analytes (Figure 1.3). 
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Figure 1.3 Schematic of ion exchange chromatography. Anion exchange 
chromatography (left) and cation exchange chromatography (right). 
 
Proteins have numerous functional groups that can have both positive and negative charges. 
Ion exchange chromatography separates proteins according to their net charge, which is 
dependent on the composition of the mobile phase. By adjusting the pH or the ionic 
concentration of the mobile phase, various protein molecules can be separated. Strong 
cation exchange is the most common ion exchange chromatography to separate peptides 
prior to LC-MS analysis as this is generally performed under acidic conditions. If a protein 
has a net positive charge at pH 7, it will bind to the negative charge of sulfonic group of the 
column solid-phase, whereas a peptide with net negative charge would not. To elute bound 
peptides, either the pH of mobile phase can be changed, altering the net charge on the 
peptide or by changing the ionic strength of the mobile phase which is generally more 
effective. The mobile phase containing increased amounts of salt (increasing ionic strength) 
is able to elute the bound proteins. Increased ionic strength results in enhanced interaction 
with the stationary phase, “shielding”  the stationary phase from the protein and allowing the 
protein to elute 26, 27. 
 
1.4.3 Reversed phase liquid chromatography 
 
Normal phase chromatography is a common method for separating analytes that are 
polar in nature. It consists of a polar stationary phase and a nonpolar mobile phase. The 
polar analyte is retained by the polar stationary phase by polar interaction. Use of more polar 
solvents in the mobile phase will elute the analyte out of column. reversed phase liquid 
chromatography separates analytes based on their interaction with the hydrophobic surface 
of a stationary phase, and is valuable for the separation of proteins and peptides. It allows 
polar molecules to elute more readily. A hydrophobic analyte is retained by a longer alkyl 
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chain length. A longer retention time depends on hydrophobicity of the analytes. Increasing 
the percentage of organic solvent elutes the analytes28,29. Silica-based reversed phase 
materials are the most widely used packing for protein and peptide analysis because they 
provide high separation efficiencies. Packing with a 5-10 μm range of particle sizes, 
containing C4, C8 or C18 provide a good utility for analytical columns (Figure 1.4).  
 
Figure 1.4 Structure of silica-based reversed phase material with a C18 chain used for 
peptide chromatography. 
 
The mobile phase is generally composed of an organic solvent, an aqueous solution and an 
ion-pairing agent. The ion pairing agent is thought to bind to the analyte molecules to 
increase their hydrophobicity, by neutralizing their charge 30. Trifluoroacetic acid (TFA) is the 
commonly used ion-pairing agent in reversed phase liquid chromatography because it is 
volatile and easily removed by lyophilisation and it has low absorption at detection 
wavelengths commonly used for peptides and proteins. However, TFA is incompatible with 
electrospray ionisation because it suppresses the electrospray signal31. Evidence has been 
presented that signal suppression is caused by strong ion pairing between the TFA anion 
and the protonated sample cation. Strong ion-pairing process thereby reduces the population 
of analyte cations and depresses the yield of electrosprayed ions32. Formic acid is commonly 
used instead.  
 
1.5 Mass spectrometry 
 
Mass spectrometers allow ions derived from analyte molecules to be  separated and 
detected based on their mass to charge ratio (m/z). It is one of the most useful analytical 
techniques and the most comprehensive tool in large-scale proteomics33. Mass spectrometry 
currently enables the analysis of protein expression34 which has also been extended to the 
identification of post-translational modifications (PTMs) such as phosphorylation35, and 
acetylation36. In addition to this qualitative analysis, mass spectrometry enables quantitative 
analysis, helping to obtain a better understanding of the integrative workings of molecular 
pathways. A mass spectrometer consists of three main components: the ionisation source, 
the mass analyser and the detector (Figure 1.5).  
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Figure 1.5 Schematic of a mass spectrometer. 
In general, the ionisation source converts sample molecules into gas-phase ions which are 
then separated by the mass analyser. In the mass analyser, ions are influenced by electrical 
and/or magnetic fields in order to separate them according to their m/z. These ions are then 
detected and a mass spectrum recorded. The results are displayed with m/z values on the x-
axis and ion signal intensities on the y-axis. 
 
1.6 Ionisation techniques 
 
 In order to be separated and detected, the analyte molecules must be ionised prior 
to analysis in a mass spectrometer. A wide variety of ionisation techniques are used for 
mass spectrometry. Proteomics type studies which analyse large biomolecules require ‘soft’ 
ionisation techniques, such as electrospray ionisation or matrix-assisted laser 
desorption/ionisation, that generate intact molecular species. Development of these ‘soft’ 
ionisation techniques was widely recognised when the 2002 Nobel Prize in chemistry was 
awarded "for the development of soft desorption ionisation methods for mass spectrometric 
analyses of biological macromolecules." to John Fenn and Koichi Tanaka. 
 
1.6.1 Electrospray Ionisation (ESI) 
 
In 1968, the ESI of macromolecules was developed by M. Dole et al.37.  To achieve 
ESI, high voltage (2–6 kV) is applied between the emitter and the inlet of the mass 
spectrometer. Nitrogen is used as both a nebulising gas and counter flow gas to aid 
desolvation and the source region is heated. Under the influence of a steep potential 
gradient, the liquid emerging from the capillary begins to form a cone shape, known as the 
Taylor cone38. At the cone tip, the surface charge density is such that repulsive forces 
exceed the surface tension and droplets form. The process that produces the small droplets 
is called budding and the diameter of the droplet is dependant on the potential, flow rate and 
solution properties. The charged droplet diameter decreases through desolvation and leads 
to an increase of the electrostatic repulsion of charges at the surface until the droplets reach 
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the stability limit (called the Rayleigh limit). Droplet fission occurs to produce the smaller size 
stable droplet (Figure 1.6). 
 
Figure 1.6 Schematic diagram of electrospray and nano electrospray ionisation. 
 
The mechanisms for the formation of gas phase ions through the ESI process are still 
unclear. Two mechanisms have been proposed. The first mechanism is the ‘charge residue 
model’ proposed by M. Dole in 196837. The coulombic fission continues to a point where 
each droplet would contain a single charged molecule then solvent evaporation will lead to a 
gas phase ion. The second mechanism is the ‘ion evaporation model’ proposed by J. V. 
Iribarne and B. A. Thomson39,40. The placing of a strong electric field near the surface of a 
liquid would raise the energy of ions to overcome the electrostatic interaction between the 
charged ions and the dipole of the surrounding water molecules. The charged ions are 
“lifted” from the surface of the solvent (Figure 1.7). 
Nano-electrospray ionisation (nESI) is a low flow electrophoresis. Typically, ESI flow 
rate is between 1μl/min and 1ml/min while nESI flow rate is between 100 and 900 nl/min. 
The capillary needles for nESI are emitters of pulled glass or fused silica with 1-10 μm open 
hole. The sample is placed into the emitter and a back pressure of ~30 PSI is applied to the 
emitter. nESI is often used in proteomics experiments because of the increased sensitivity of 
the analysis. The droplets formed in nESI are smaller than those produced during ESI. 
Therefore, it reduces the amount of evaporation required for the formation of desolvated 
charged ions and more tolerant of salts due to the increased isolation of salt ions. 
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Figure 1.7 Schematic diagram of the charged residue model and the ion evaporation 
model.  
 
1.6.2 Matrix-Assisted Laser Desorption/Ionisation (MALDI) 
 
In 1985, matrix-assisted laser desorption/ionisation was first introduced by Karas 
and Hillenkamp41. They analysed a mixture of alanine and tryptophan and observed an 
intense signal of the alanine alongside the tryptophan signal using one tenth of the irradiation 
of 266 nm from neodymium-doped yttrium aluminium garnet laser for the ionisation of 
alanine alone. It was concluded that tryptophan must be regarded as an absorbing matrix 
resulting in proton transfer to the alanine residues. In 1988, they further demonstrated the 
ionisation of proteins over 10 kDa using bovine serum albumin at 67 kDa42 and MALDI has 
been used successfully to analyse biomolecules up to 300 kDa43. MALDI is performed by co-
crystallisation of analysts and an ultraviolet (UV) absorbing matrix, usually an organic acid. 
The mixture is applied on a suitable target, often made from stainless steel or gold44,45. Three 
matrices most commonly used are α-cyano-4-hydroxycinnamic acid (alpha-cyano), 2,5-
dihydroxybenzoic acid (DHB) and 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid). 
The selection of the matrix is dependent on the analyte. Alpha-cyano is used for the analysis 
of smaller peptides, while sinapinic acid is used for the ionisation of proteins. DHB is used 
primarily for the analysis of modified peptides such as phospho- and glyco- peptides46. 
Saturated solutions of these matrices are made up in water and an organic solvent (most 
often acetonitrile). Trifluoroacetic acid (TFA) is also added to 0.1% (v/v) to increase the 
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efficiency of proton transfer.  The matrix solution is then added to the analyte mixture 
typically in equal volumes, applied on a target and allowed to dry. When the analytes are co-
crystallised, the surface is irradiated with a pulsed laser beam, causing transition of the 
matrix and the co-crystallised analyte from solid to gas. After that, the matrix desolvates from 
the surface of the analyte ions and the co-crystallised analyte becomes charged by the 
acceptance of a mobile proton from the associated UV absorbing matrix. The charged ions 
enter the mass analyser.  MALDI is more resistant to salts and contamination than ESI for 
the analysis of biomolecules. It also requires only fmol level of the analyte (Figure 1.8).  
 
Figure 1.8 Depiction of Matrix-Assisted Laser Desorption Ionisation. A schematic 
diagram of ablation of a co-crystallised analyte with a pulsed laser. Through the process of 
desolvation a proton is transferred from the matrix ion to the analyte ion, producing charged 
ions. 
 
The precise mechanism of the proton transfer is still not fully understood. There are a 
number of proposed mechanisms to explain the desorption process47,48. According to these 
mechanisms, it is generally accepted that ionisation occurs through proton transfer during 
the desorption process. Multiply and singly charged ions may be produced during this 
ionisation however, only singly charged species are detected. It is supposed that highly 
charged positive ions of proteins may be reduced to singly charged ions, perhaps by ion-
electron recombination with photoelectrons in the MALDI plume49.  
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1.7 Mass Analysers 
 
 Once gas phase ions have been produced, they need to be separated according to 
their m/z. There are many different types of mass analysers. In this section, the quadrupole 
mass filter, time of flight, quadrupole ion trap and ion cyclotron resonance are described. 
 
1.7.1 Quadrupole Mass analyser 
 
 W. Paul invented the quadrupole mass filter along with the quadrupole ion trap in 
195350. Quadrupole mass analysers consist of four parallel metal rods (Figure 1.9). 
 
Figure 1.9 Schematic of quadrupole mass analyser. Figure reproduced from Paul et al.50. 
 
The application of opposing potentials upon adjacent rods allows the production of a RF 
field. The voltages that are applied to the quadrupole are shown in equations 1.1 and 1.2. 
 
Фo= + (U-Vcos (ωt))     Equation 1.1 
–Фo= - (U-V cos (ωt)) Equation 1.2 
 
Where Ф is the electrical potential. U is a constant (DC) voltage. Vcos (ωt) is an alternating 
(AC) voltage. ω is the angular frequency (rad s-1) and ω= 2лf where f is the frequency.  
When ions are injected into the quadrupole in z-direction, the applied voltage on each pair of 
connected rods switches from positive to negative potential causing the ions to move in an 
oscillating motion. The oscillations of the ions are dependent on the m/z. Ions that are 
unstable under these conditions are lost because of the collision with the electrodes or the 
inside of the instrument casing50. A mass spectrum is obtained by monitoring the ions 
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passing through the quadrupole filter as the voltages on the rods are varied. For any given 
set of DC and RF potentials, only ions of a specific m/z can pass through the quadrupoles. 
Ions will have a stable trajectory as long as x and y remains less than r0 (r0 is half the 
distance between the rods). The Mathieu equations establish a relationship between the 
oscillatory motion of an ion and the coordinates of an ion (Equation 1.3). 
 
d2u/d ζ 2 + (au-2qu cos 2ζ )u = 0 Equation 1.3 
 
Where u stands for either x or y, ζ= ωt/2 and au and qu represent the x and y dimension 
respectively. au and qu are defined using the following: 
 
au = 8zeU  Equation 1.4 
      Mω2r02 
 
qu =  4zeV          Equation 1.5 
    Mω2r02 
 
Where ze is the charge of an ion. M is mass of an ion. au is the effect of the application of a 
DC voltage on the motion of the ions and qu is the effect of an AC voltage.  
According to the Mathieu equations, stable motion refers to the ions’ oscillation through the 
quadrupole in the x-y plane passing through the field in the z-direction without hitting the 
rods.  Unstable motion occurs as the amplitudes of the ion motion grows exponentially in the 
x or y direction causing the ions to collide with the rods. When quadrupole r0 is constant and 
ω is maintained constant whilst only U and V are varied. The possible behaviour of the ions 
is shown by the stability diagram (Figure 1.10).  The ions are maintained in a stable 
trajectory as long as U and V are within the limits of their stability area. Outside this area, 
ions will be lost as the orbits become infinitely large. The gradient of the scan line will 
determine the optimal ion transmission and thus resolution of the quadrupole. The optimum 
gradient will be where the scan line cuts the very top of the stability diagram. 
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Figure 1.10 Stability areas as a function of U and V for the trajectory of ions of 
different m/z (m1< m2< m3) moving through the quadrupolar field. Figure reproduced 
from Paul et al. 51.  
 
1.7.2 Quadrupole Ion Trap 
 
 W. Paul and co-workers invented the quadrupole ion trap alongside the 
quadrupole mass filter in 195350. He shared the Nobel Prize in Physics in 1989 for this work. 
Three hyperbolic electrodes, consisting of a ring and two end caps, form the core of this 
instrument (Figure 1.11).  
 
Figure 1.11 Schematic diagram of a quadrupole ion trap. Figure adopted from Paul et 
al.51.  
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In 1983, the first mode of operation was developed to simplify the use of the instrument. Ions 
were pulsed into the trap and were then sequentially ejected from the trap into an electron 
multiplier detector52. Another significant development was the use of helium gas (1 mTorr) 
within the trap, reducing the kinetic energy of the ions by collision and achieving a 
concentration in the centre of the device53. The addition of helium gas thus allows the 
formation of an ion packet, which is much more efficiently ejected from the trap than a diffuse 
cloud of ions. This improves the resolution of the instrument. ESI is typically used as the ion 
source of ion trapping instruments. Ions are focused through a series of electrostatic lenses, 
then they are injected into the trap. The injection of ions into the trap is done through a 
pulsing electrostatic ion gate, which pulses (V-) and closes (V+). The stability of ions within 
the ion trap is also dependant upon the Mathieu equations (Equations 1.3, 1.4 and 1.5). The 
"stability diagram" shows a theoretical region where radial and axial stability overlap (Figure 
1.12). Depending upon the amplitude of the voltage placed on the ring electrode, an ion of a 
given m/z will have az, qz values that will fall within the boundaries of the stability diagram, 
and the ion will be trapped. If the az, qz values at that voltage falls outside of the boundaries 
of the stability diagram, the ion will hit the electrodes and be lost. 
 
Figure 1.12 Stability diagram for ions within a quadrupole ion trap. Figure reproduced 
from Paul et al. 51.  
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Ions oscillate in the trap with a frequency known as the ‘secular frequency’. A mass 
spectrum is generated by sequentially ejecting ions from low m/z to high m/z. This is done by 
scanning the amplitude of the fundamental RF voltage of ring electrode to make ion 
trajectories sequentially become unstable. Ions are ejected through holes in the endcap 
electrode and detected using a dynode detector. There are two methods of ion isolation 
within an ion trap; the first is manipulation of az and qz to destabilize all ions other than the 
ion for isolation. The second is ejection of unwanted ion species by resonance excitation of 
the secular frequency of the ions. If the amplitude of the resonance signal is large enough, 
ions will be ejected from the trap.  
 
1.7.3 Time of Flight 
 
The time of flight (ToF) mass analyser was first introduced commercially in 195554,55. 
The general principle of time of flight mass spectrometry is acceleration of ions by an electric 
field and entering into a field free region towards a detector. Ions of the same charge have 
the same kinetic energy, while their velocity is dependent on their m/z. The time taken for an 
ion to travel from source to detector through the field-free region can be used to calculate 
their velocity and thus the m/z of the ions of interest. The heavier the ion, the longer it will 
take the ion to reach the detector (Equation 1.6).  
 
m/z =2eEs(t/d)2 Equation 1.6 
 
Where e is the charge of the electron, E is the extraction pulse potential, s is the length of 
the flight tube over which E is applied, t is the measured time of flight of the ion, d is the 
length of the field free drift zone 55.  
Ions of the same m/z theoretically have the same initial kinetic energy. However, in practice 
the kinetic energy is not equally distributed to all of the ions upon ionisation and therefore an 
energy distribution for each m/z arises. To overcome this difference in kinetic energy the 
reflectron ToF was developed in 1973 by Mamyrin et al.56. The reflectron grid is applied at 
the end of the drift zone to increase the path length for ions of greater kinetic energy, thereby 
equalising arrival times at the detector.  Reflectron ToF consists of a series of electric fields 
which repulse the ions back along the flight tube to a reflectron detector57. The reflectron ToF 
increases peak resolution when compared with linear ToF. Post-source decay refers to the 
fragmentation of molecular ions during their flight time in the mass spectrometer, subsequent 
to ionisation and acceleration away from the ionisation source. The product ions have almost 
the same velocity as their precursors, but differ in their kinetic energies. Since kinetic energy 
is directly proportional to mass, the smaller product ions have less kinetic energy than the 
precursors. The linear TOF analyser cannot resolve the ions because the fragment ions and 
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precursor ions all have the same velocity. The reflectron ToF can separate precursor ions 
from the product ions (Figure 1.13).  
 
Figure 1.13 Schematic diagram of linear and reflectron time of flight. Figure adopted 
from Carr et al.58. 
 
Delayed extraction is a method used with a ToF to improve mass resolution. The 
ions are allowed to cool for ~150 nanoseconds before being accelerated into the ToF 
analyser. Ions produced from ion source with greater kinetic energy have a higher velocity. 
During the delay time, they move closer to the extraction electrode. The slower ions with less 
kinetic energy stay closer to a surface of the target electrode. When the accelerating voltage 
is applied, the ions further from the extraction electrode are accelerated at a greater 
potential. With the proper delay time, the slower ions will receive enough extra potential 
energy to travel with the same velocity with the faster ions. Ions of the same m/z will reach 
the detector in the same time (Figure 1.14). This process results in an increase in both 
resolution and mass accuracy. 
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Figure 1.14 Schematic diagram of delayed extraction.  
 
1.7.4 Fourier Transform Ion Cyclotron Resonance Mass spectrometry 
 
 Fourier transform ion cyclotron resonance (ICR) is a mass analyser for determining 
ions which  are influenced by magnetic fields in order to separate them. At the beginning, 
this technique only remained an academic tool59. In 1974, the cyclotron was coupled to 
Fourier transform (FT) to allow accurate mass measurement of ions by A.G. Marshall and 
M.B. Comisarow at the University of British Columbia 60. In the basic FT-MS instrument, the 
ions are generated in the source and pass through a series of pumping stages at 
increasingly high vacuum. When the ions enter the cell, pressures are in the range of 10-10 to 
10-11 mBar. The cell is located inside a spatially uniform static superconducting high field 
magnet (typically 4.7 to 13 Tesla) cooled by liquid helium and liquid nitrogen. When ions are 
within the analyser, they are maintained in a Penning trap (a magnetic field with electric 
trapping plates) and influenced by the Lorentz force. The axis of the Lorentz force and the 
magnetic field are perpendicular (Equation 1.7)61.    
 
F=qv Bsinθ     Equation 1.7 
 
Where q is the charge on the ion, v is the velocity of the ion, B is the strength of the magnetic 
field, and θ is the angle between the axis of the force of the ion and the axis of the magnetic 
field. According to the influence of the magnetic field, an ion begins to move in a circular 
motion (Figure 1.15).  
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Figure 1.15 Depiction of ion cyclotron motion. 
 
This motion is known as cyclotron motion. The frequency of rotation of the ions is dependent 
on their m/z ratio (equation 1.8 and 1.9). 
 
f =  qB        Equation 1.8   
          2πm 
 
ω = qB       Equation 1.9       
                m  
 
Where m is the mass of the ion, B is the magnetic field strength, ω is angular frequency and 
f is cyclotron frequency.  
At this stage, no signal is observed because the radius of the motion is very small and ions 
of the same m/z do not have coherent motion. Excitation of each individual m/z is achieved 
by a swept RF pulse across the excitation plates of the cell. Each individual excitation 
frequency will couple with the ions’ natural motion and excite them to coherent motion at 
orbits of increased radii where they induce an alternating current between the detector 
plates. The cyclotron frequency will be determined by velocity as well as by radius. The 
coherent motion at elevated radius is maintained after excitation until collisions with residual 
gas lead to incoherent motion and reduced radii.  This is the reason why it is important to 
achieve very high vacuum in an ICR cell to maintain the image current associated with 
coherent motion for as long as possible. Although the RF sweep is made up of a series of 
stepped frequencies, it can be considered as exciting all frequencies simultaneously. This 
results in the measurement of all the ions in one go producing a complex frequency (Figure 
1.16).  
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Figure 1.16 Depiction of Fourier transform mass spectrometry. Figure adopted from 
Marshall et al 61. 
 
The detection of motion of this ion packet gives a time-domain signal consisting of the 
difference in current induced on the detector plates. This signal is digitised and subjected to 
Fourier transformation to yield a spectrum of ion cyclotron frequencies, which then converted 
to a spectrum of m/z62 (Figure 1.17).  
 
Figure 1.17 Conversion of a time domain image into m/z. Figure adopted from Marshall A. 
G. et al.63. 
 
1.8 Tandem Mass Spectrometry 
 
 Tandem mass spectrometry (MS/MS) involves multiple steps of mass spectrometry 
selection and fragmentation occurring between the stages.  The fragmentation can occur 
from an activated dissociation process. For peptide fragmentation, the peptide backbone is 
dissociated producing fragmented ions. The fragmentation pattern is specific to the method 
used to produce those fragment ions and can be used to diagnose peptide sequence64,65. 
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Each of these techniques produce fragment ion from the breakage of different bonds along 
the peptide backbone. The nomenclature of fragmented ions suggested by Roepstorff and 
Fohlman in 198466 and modified by Biemann et al. 67 is detailed in (Figure 1.18).  
 
Figure 1.18 Common Nomenclature of fragment ions produced by backbone cleavage. 
Figure reproduced from Biemann et al 67. 
 
Other commonly observed types of peptide fragment ions are internal fragment ions and 
immonium ions, both arising from double cleavage of the peptide chain (Figure 1.19).  
 
 
Figure 1.19 Structure of internal fragment ion and immonium ion. Figure reproduced 
from Biemann et al.67. 
 
Tandem mass spectrometry can take place in either space or time depending on the 
instrument. Tandem-in-space instruments couple two physically distinct mass analysers. 
This allows the decomposition and analysis of the product ions in different mass analysers. 
Triple quadrupole, ToF-ToF and Q-ToF are tandem-in-space instruments. Tandem-in-time 
instruments perform the appropriate sequence of events in an ion storage device. They are 
programmed to isolate, fragment and detect product ions in the same instrument. 
Quadrupole ion traps and FT-ICR MS instruments apply tandem mass spectrometry on a 
time domain. They are capable of performing multiple stages of tandem mass spectrometry. 
Tandem mass spectrometry can be performed in one of four main analysis modes; 
product ion analysis, precursor ion analysis, neutral loss analysis and selected/multiple 
reaction monitoring (Figure 1.20). (Only single or sequential product ion analysis is directly 
achievable on tandem-in-time instruments.) 
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Figure 1.20 Schematic diagram of the four main analysis modes used for MS/MS; The 
product ion analysis, precursor ion analysis, neutral loss analysis and selective reaction 
monitoring. Figure reproduced from Hoffmann et al. 68. 
 
For a product ion analysis, a specific m/z is selected in the first mass analyser (M1). This 
specific ion is then transmitted to the collision cell where fragmentation takes place. All of the 
resulting ions are then scanned in the second mass analyser (M2). Product ion analysis has 
become the most common method used for routine peptide identification. For a precursor ion 
analysis, the entire mass range is scanned in M1, M2 is then fixed to monitor and transmit 
product ions of a specific m/z ratio only. The mass spectrum contains only the specific 
precursor ions which generate specific product ions51. A neutral loss analysis determines the 
m/z of precursor ions that fragment to produce the loss of a specified neutral mass. This is 
achieved by offsetting the scans of M1 and M2.   Neutral loss scanning is commonly used for 
PTM analysis e.g. loss of phosphoric acid. For selected reaction monitoring (SRM), the 
compound must be known and have been well characterised previously before doing this 
type of experiment. Only fragment ions of specific m/z derived from a particular precursor ion 
will generate a signal.  This is extended with multiple reaction monitoring (MRM), where a 
number of specific product ions derived from a precursor ion of interest are used.  This 
increases the sensitivity of identification and the precision of quantification 66. 
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1.8.1 Collision Induced Dissociation (CID) 
 
 Collision induced dissociation is a mechanism to fragment ions in the gas 
phase. The ions are accelerated by a defined electrical potential - keV for high energy CID 
and up to 200eV for low energy CID. The normal collision cell is a quadrupole (or other 
multipole) in RF-only mode. The collision gas is usually helium, argon or xenon. The 
collisions with inert gas results in some of the kinetic energy being converted into internal 
energy of the ion (vibrational excitation). In low energy CID ions stay in the collision cell for 
~10-100μs, while they spend < 1μs in the cell in high energy CID. The collision leads to 
fragmentation. Low energy CID is the most common method of fragmentation used for 
studying proteins and peptides.  The development of CID began with K.R. Jennings69 and F. 
W. McLafferty70 who applied CID for fragmenting small aromatic compounds in 1968. After 
that, D. F. Hunt et al. first applied CID to the identification of oligopeptides in a triple 
quadrupole instrument71,72. A first quadrupole was set to select the precursor ion and passed 
through to the second quadrupole where the collisions with argon atoms took place. The 
fragmented ions were then passed through to the third quadrupole for mass analysis. 
Analysis of the product ions permits deduction of the precursor peptide sequence73.  
 CID was first demonstrated in a quadrupole ion trap mass spectrometer in 
1987 by Louris et al.74 by applying to the end-cap electrodes a small supplementary RF 
voltage, at the same secular frequency as the ion of interest. This produces an increased 
amplitude of ion motion for ions of that particular m/z, which then fragment after collisions 
with the helium buffer gas. This has been the most popular method used for CID in the 
quadrupole ion trap mass spectrometer. 
For collisional activation, there are two frames of reference; the laboratory frame of 
reference and the centre of mass frame of reference. For laboratory frame of reference, the 
neutral gas is considered to be at rest and the precursor ion moves towards the stationary 
neutral target. The collision energy is defined as the kinetic energy of the precursor ion. For 
the centre of mass frame of reference, the neutral mass and precursor ion are considered to 
be travelling towards each other. The maximum translational energy of target molecules 
converted into internal energy under inelastic conditions is given by the collision energy in 
the centre of mass frame of reference (Ecm). 
 
Ecm  = Elab (mt/(mt+mp)  Equation 1.11 
 
Where mt is the target mass, mp is the precursor mass and Elab is ion kinetic energy in the 
laboratory frame of reference. Collision energy is categorized into two group; high energy 
(Elab in the keV range) and low energy (Elab up to 200 eV). 
According to several researchers, the mobile proton model provides a useful 
conceptual framework for peptide fragmentation75, 76, 77. The mobile proton model proposes 
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that the fragmentation of most protonated peptides requires the presence of a proton at the 
cleavage site also called “charge-directed”. An amino acid side-chain sequesters a proton, 
which then moves from the basic side-chain to the peptide backbone inducing dissociation. 
Energy is required for the mobilization of a proton along the peptide backbone.  
Gaskell and co-workers reported a series of studies to understand CID 
mechanism on peptides. During CID, doubly protonated precursor tryptic peptides are 
cleaved more effectively than their singly protonated specie. This results from the affinity for 
a proton of the basic side chain in the C-terminal residue. Introduction of a second proton, 
with no strongly favoured location, promotes fragmentation. The introduction of an acidic 
residue in a tryptic peptide enables to balance the charge on the basic arginine residues, 
enabling a single ionising proton to mobilize to less basic sites along the peptide backbone78. 
Tryptic peptide containing two arginine, two histidine or two lysine residue decreased the 
fragmentation efficiency of doubly protonated precursors due to increased basicity79,80. 
Arginine containing peptides require greater energy for fragmentation than lysine containing 
and non basic side chains as the higher basicity of arginine means the proton mobilises less 
easily. Acetylation at the amino terminus and derivatisation of the arginine side chain leads 
to a decrease in basicity and a corresponding lower energy onset for fragmentation than for 
the unmodified form of the peptide75.  
The mechanism of formation of b and y ions was proposed by Yalcin et al. 81, 82. 
The ionising proton is transferred to the backbone of the peptide and then the fragmentation 
occurs via a cyclic intermediate. According to these mechanism b-ions have a cyclic 
oxazolone structure and y ions are linear (Figure 1.21).  
 
Figure 1.21 Proposed mechanism for the formation of b and y-ions.  Oxazolone b ion 
formation along with y-ion formation. Figure reproduced from Yalcin et al. 82.  
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The formation of this oxazolone intermediate explains the lack of observation of b1-ions in 
unmodified peptides. The cyclic b ions can rearrange to product the linear b ions (Figure 
1.22). However, the cyclic form is more stable than linear form. The presence of the linear 
acylium ion formation was also observed by the fragmentation of doubly protonated b-series 
fragment ions 83. The acylium form of the b ion can readily lose carbon monoxide (CO) giving 
rise to an a type ion. 
 
 
Figure 1.22 Structure of protonated oxazolone and acylium ion. Figure reproduced from 
Yalcin et al 82.  
 
A cyclic intermediate was confirmed by Harrison et al.84 Scrambling of the b-series ions 
resulting from ring closing were identified and the fragmented ion unlike the original peptide. 
Riba et al. detected a cyclic b5 ion formation using the ion mobility data, which also 
supported the forming of the cyclic intermediate85.  
 
1.8.2 Infra-Red Multi Photon Dissociation (IRMPD) 
 
Infra-red multi-photon dissociation is a technique used to fragment ions by exciting 
the precursor ions using photon absorption. It is typically used in an FT-ICR MS and ion trap 
instruments. The precursor ions are stored within the cell and the infrared laser beam is 
injected through the ion packet. This increases the internal energy of the peptide ions 
inducing fragmentation. Typically b and y fragment ions are produced when peptide ions 
undergo IRMPD. Normally, gas molecules are required to provide very low energy collisions 
with trapped analyte ions. This decreases their kinetic energy and helps their movement to 
the centre of the cell86. IRMPD is a vibrational heating technique. Therefore, the 
fragmentation mechanism and the resulting ions are similar to CID.  
 
1.8.3 Electron Transfer Dissociation (ETD) 
 
Electron capture dissociation (ECD) was first developed by Zubarev et al. in 199887. 
It is a low energy fragmentation technique which involves a multiply protonated ion 
interacting with a free electron to form an odd-electron ion due to further fragmentation. 
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During ECD radical site directed cleavage of the peptide backbone occurs primarily at the C
-N bond rather than at the amide linkage. ECD can only be carried out using an FT-ICR 
instrument due to the ability of trapping the electrons into the cell. The advantageous 
fragmentation patterns observed from ECD due to the development of electron transfer 
dissociation (ETD) in a cheaper more widely available mass spectrometer. ETD is the 
process whereby multiply protonated peptides undergo ion-ion reactions with singly-charged 
radical anions, resulting in their fragmentation. In 2004, D. Hunt first used anthracene anions 
for ETD of multiply protonated peptides in a radio frequency quadrupole linear ion trap88. 
Multiply protonated peptide ions are commonly generated by ESI and enter into the ion trap. 
Anionic reactive species are generated in a chemical ionisation (CI) source with a methane 
buffer gas and are sequentially injected into the ion trap, where the radical anions react with 
the peptide cations (Scheme 1.1). Commonly used anions are anthracene (C14H10) and 
fluoranthrene (C16H10).  Transfer of one or more electrons from the fluoranthene radical 
anions to the multiply charged peptide promotes radical-induced dissociation along the 
peptide backbone and generates c ions and radical z• ions. 
 
[M+4H]4+ + C16H10-• → [M+4H]3+• + C16H10 Scheme 1.1 
 
The structure of c-type ions formed by ECD was published by Turecek and co-workers89 
(Figure 1.23). 
 
 
Figure 1.23 Formation of c-Type Ions from a doubly charged peptide. Figure reproduced 
from Turecek and co-workers89 
 
It is possible to use ETD to promote fragmentation of intact proteins, however it generates 
highly charged fragments that may be difficult to resolve on mass spectrometers. Sequential 
ion/ion reactions has been implemented to solve this problem88. Following the electron 
transfer reaction, fluoranthene radical anions are removed and replaced by even-electron 
benzoate anions. These anions remove protons from the multiply charged fragment ions 
and, thus, reduce their charge. The result of this second ion/ion reaction is a simplified 
spectrum that is enriched in fragments of reduced charge (Scheme 1.2). 
 
[M+7H]7+ + 6C6H5COO- → [M+H]+ + 6C6H5COOH Scheme 1.2 
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1.8.4 LIFT ToF/ToF tandem Mass Spectrometry  
  
Because of the predominantly singly protonated ions in MALDI, fragmentation 
efficiencies are generally low90. In 1991, post source decay (PSD) was first developed by 
Kaufmann et al. with the analysis of metastable ions91, 92, 93. PSD is the process that ions 
decay while they fly in the field free flight path within a ToF instrument. Westmore and co-
workers applied PSD to the analysis of biomolecules to sequence peptides94. In 2003, 
Suckau D et al. developed LIFT ToF/ToF tandem MS95. According to this technique, the 
product ion resolution is increased in comparison with PSD on a standard reflectron 
instrument. After PSD in drift region, the timed ion selector (TIS) selects the precursor ion 
and their corresponding fragment ions according to the time that ions arrive at this region. 
Selected ions are passed through by turning off the gate voltage for a particular portion of 
time. Selected precursor ion and its fragments have the same velocity upon the entrance to 
the LIFT cell. The LIFT cell consists of three components: a potential lift, a focusing cell and 
a post-acceleration cell. The potential lift consists of adjacent rods where a voltage of 19 kV 
is applied. A focusing cell is to modulate the speed of the ions. The ions are held at the 
potential of 19 kV until the third grid. At the third grid, the potential is decreased to 2-3 kV 
and ions are accelerated to detector depending on their mass95 (Figure 1.24).  
 
 
Figure 1.24 Schematic diagram of the Bruker Ultraflex II MALDI-ToF-ToF. Figure 
reproduced from Suckau et al 95.  
 
1.9   Protein Quantification 
 
 The study of the genome and relative mRNA expression cannot provide details on 
all of the changes in components of cell systems. The mRNA changes do not directly relate 
to changes in protein levels, due to different rates of translation, posttranslational 
modification, subcellular localization and degradation, which emphasises the requirement for 
evaluating protein levels. In addition, the processes of post-translational regulation of protein 
levels and activity, such as phosphorylation, glycosylation, acetylation and ubiquitination, all 
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need quantification. Most quantitative proteomics experiments use a relative method. The 
abundance of a protein is expressed as a relative term - for example protein A is n-times 
more abundant in sample X than in sample Y. However, relative quantification is limited to 
identifying changes in the amount of a protein with respect to a second cellular state, and 
samples vary even within control sets of the same organism. When comparing samples 
analysed at different times and within different laboratories, absolute quantification allows 
direct comparison. More recently, absolute quantification has become possible providing 
definitive protein amounts for example using QconCAT96. In this thesis, isobaric tagging for 
relative and absolute quantification (iTRAQ) was used for relative quantification. 
 
1.9.1 Isobaric tag for relative and absolute quantification (iTRAQ) 
  
 iTRAQ reagents are a multiplexed set of isobaric reagents which are amine specific. 
They label peptides to give identical masses but fragment to give product ions 
distinguishable by tandem mass spectrometry. Post-translational modifications are 
maintained upon incorporation of this label. iTRAQ reagents are non-polymeric, isobaric 
tagging reagents consisting of a reporter group, a balance group, and a peptide reactive 
group (Figure 1.25).  
 
Figure 1.25 Structure of iTRAQ. iTRAQ 8-plex molecule consists of reporter group, 
balance group and peptide reactive group.Figure reproduced from Sadowski et al 97 
 
Recently, an 8-plex version of the iTRAQ reagents was developed98. The peptide reactive 
group covalently binds an iTRAQ reagent isobaric tag at each lysine side chain and N-
terminus group of a peptide.  During CID, the isobaric tag cleaves between the reporter 
group and the balance group, yielding reporter peaks in the low-mass region between m/z of 
113, 114, 115, 116, 117, 118, 119, and 121 m/z, which is free of other common ions. iTRAQ 
enables the differential quantification of up to 8 different samples (i.e. cell strains or can be 
used for duplicate analyses) by calculating the peak areas of these resultant ions which 
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represent the relative amount of given peptides in the respective sample. Recently. The 
iTRAQ approach provides quantitative data for all of the peptides analysed during MS. 
Advantages of iTRAQ are it is possible to obtain data on more peptides from the same 
protein simultaneously when compared with other methods. Second, because the tags are 
isobaric, the signal from up to eight samples is summed in the survey MS scan, providing an 
increase in sensitivity. The iTRAQ 4-plex workflow is shown in Figure 1.26 99, 100.  
 
 
Figure 1.26 Schematic of iTRAQ 4-plex workflow. The method is based on the covalent 
labeling of the amine groups of tryptic peptides. These samples are then pooled and 
fractionated by nano-liquid chromatography and analysed by tandem mass spectrometry. 
Figure adopted from Sadowski et al97. 
 
 
 
1.9.2 Data analysis 
 For MS analysis, peptide mass fingerprinting (PMF) is the simplest method of 
peptide identification 101, 102. Typically in PMF, proteins are digested with trypsin prior to mass 
spectrometric analysis. Peak lists are generated into a raw data file. The peptide masses are 
then searched against a protein database commonly using a search algorithm such as 
Mascot103 or Protein Prospector104, and proteins are identified accordingly. Identification is 
achieved by matching observed peptide masses to theoretical masses from a protein 
sequence database. For MS/MS analysis, the m/z values of the fragmented ions present 
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within the tandem mass spectra and their precursor are also converted into peak lists and 
searched against theoretical spectra to obtain sequence information. In addition to 
sequence, tandem MS of peptide sequences enables the definition of sites of PTMs and can 
allow the identification of the presence of isoforms. All of the data in this thesis were 
evaluated for the rate of false positives. The data were repeatedly searched, using identical 
search parameters, against a database in which the sequences have been reversed (decoy 
database).  
1.10 Aims and Objectives 
 
 A major objective of this thesis is to identify the protein target(s) of (R)-
lacosamide. This may lead to the characterisation of the target(s), mechanism(s) of (R)-
lacosamide function and elucidate alternative pathways of seizure control. Prof. Harold Kohn 
from University of North Carolina developed the strategy for enriching target proteins from 
mouse brain lysate using ligand based affinity purification. The lacosamide molecule is 
derived with two functional groups, an affinity bait (AB) and a chemical reporter (CR). The 
affinity bait is for binding covalently with amino acid residues in the target protein(s). The 
chemical reporter is for reacting with a biotin (or other) probe and used for subsequent 
streptavidin affinity purification of bound target proteins (Figure 1.27).  
 
Figure 1.27 Schematic of strategy for enriching target proteins from mouse brain 
lysate. Figure provided by Prof. Harold Kohn. Nu represents nucleophilic amino acid. 
 
In this thesis, four affinity baits have been used to search the brain proteome for site(s) and 
targets of drug binding with four (R)-lacosamide analogues (Figure 1.28). (R)-lacosamide 
analogue A and B consist of electrophilic affinity bait. (R)-lacosamide analogue C and D 
consist of photoreactive affinity baits.  The electrophilic affinity baits are naturally reactive 
with nucleophillic groups of amino acids for example lysine and cysteine.  This process can 
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be pH, time, and temperature dependent. The photoreactive affinity baits are activated by 
exposure to light (wavelengths vary from 300nm 365nm).  During this time the probes are 
very reactive and form a covalent bond with any amino acid through C-H insertion.  There is 
no specificity for any amino acid for the photoreactive affinity baits. All of these analogues 
retain the pharmacological properties of (R)-lacosamide (Figure 1.28). 
 
Figure 1.28 Structures of (R)-lacosamide analogue A, B, C and D. Figure provided by 
Prof. Harold Kohn. 
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Figure 1.29 Reaction of electrophilic and photoreactive affinity bait of (R)-lacosamide 
analogue A, B, C and D.  
 
 
The (R)-lacosamide analogue was captured with target protein in the reaction mixture for 
example mouse or rat brain lysate. The modified proteins were either reacted with the biotin 
probe or rhodamine probe (Figure 1.30).  
 
Figure 1.30 Structures of biotin and rhodamine probe. Figure provided by Prof. Harold 
Kohn. 
 
The biotinyl (R)-lacosamide analogue bound proteins were detected selectively by isolating 
from the mixture using affinity-based streptavidin chromatographic methods and subsequent 
mass spectrometry. The rhodaminyl probe was used for detection of gel electrophoresis. 
 
                            Experimental Chapter 2 
  46 
CHAPTER 2 
Experimental 
 
2.1. Materials 
 
All of the lacosamide related samples, the analogues and covalently modified amino 
acids, peptides and proteins were received from Professor Harold Kohn and his coworkers 
(Division of Medicinal Chemistry and Natural Products, UNC Eshelman School of Pharmacy, 
University of North Carolina, Chapel Hill, North Carolina).  
 The following chemicals were purchased from Sigma Aldrich (Poole, UK): Tris-HCl, 
trypsin proteomics grade, sodium dodecyl sulfate, glycerol, β-mercaptoethanol, bromophenol 
blue, acrylamide, N,N’-methylene bisacrylamide, ammonium persulfate, N,N,N,N-
tetramethyl-ethylenediamine, isopropanol, glycine, Coomassie Brilliant Blue R-250, 
methanol, acetic acid, sodium thiosulfate, silver nitrate, sodium carbonate, ammonium 
bicarbonate, acetonitrile, potassium fericyanide, dithiothreitol, iodoacetamide, formic acid, 
formalin, trifluoroacetic acid, ammonium chloride, ammonium phosphate, potassium 
phosphate, potassium chloride, potassium phosphate, biotin, [Glu1]-fibrinopeptide B (Glu-
Fib), alpha-cyano-4-hydroxycinnamic acid, sinapinic acid, ethylenediaminetetraacetic acid 
(EDTA), ethylene glycol tetraacetic acid (EGTA), guanidine HCl, HPLC grade isopropanol, 
HPLC grade methanol, HPLC grade acetonitrile, HPLC grade water, HPLC grade formic 
acid, HPLC grade trifluoroacetic acid. 
Spin concentrators for buffer exchange with 5 kDa molecular weight cut off for 1.5 ml 
of buffer were purchased from Agilent (Lakeside, UK). Gel tanks and glass plates were 
purchased from Bio-Rad (Hemel Hempstead, UK). C18 and C4 micro and macro trap columns 
were purchased from Michrom Bioresources (CA, USA). C18 ZipTipsTM were purchased from 
Millipore (MA, USA). Streptavidin HP Spintrap columns were purchased from GE Healthcare 
(Buckinghamshire, UK). iTRAQTM reagents were purchased from Invitrogen (Paisley, UK). 
Protein Standard II for MALDI-ToF calibration was purchased from Bruker Daltonics 
(Coventry, UK). Cation exchange cartridge (20 x 2.3 mm) was purchased from Applied 
Biosystems (Foster city, CA). C18 PepMapTM 100, 3 µm, 100 Å (Dionex, UK) 75 µm x 15 cm 
reversed phase liquid chromatography capillary columns were purchased from LC Packings 
(Sunnyvale, CA). Polysulfoethyl columns were purchased from PolyLC (Columbia, Mary 
Land). Gold coated borosilicate nanospray needles were purchased from Proxeon (Odense, 
Denmark). 
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2.2. Methods 
2.2.1. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
 Protein samples were denatured by heating for 5 min at 95 ºC in sample buffer (60 
mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol and 
bromophenol blue). A 10% separating gel was prepared as follows: 10% (w/v) acrylamide, 
0.3% (w/v) N,N’-methylene bisacrylamide, 250 mM Tris-HCl (pH 8.8), 0.1% (w/v) SDS, 0.1% 
(w/v) ammonium persulfate and 0.06% (v/v) N,N,N,N-tetramethyl-ethylenediamine. The 
solution was poured into a mini-gel between two glass plates (10 cm x 7 cm x 1 mm) 
followed by a layer of isopropanol. After gel polymerisation, the isopropanol was removed 
and a stacking gel solution was prepared, 5% (w/v) acrylamide/ 0.1% (w/v) N,N’-methylene 
bisacrylamide, 200 mM Tris-HCl (pH 6.8), 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulfate 
and 0.1% (v/v) N,N,N,N-tetramethyl-ethylenediamine. The solution was poured over the 
separating gel, a comb inserted to form the wells for sample loading and let to polymerise for 
at least 10 min.  Electrophoresis was performed by immersing the gels in running buffer (25 
mM Tris-HCl, 192 mM glycine (pH 8.3) and 0.1% (w/v) SDS). The denatured protein samples 
were loaded into each of the wells. Constant electric current (60 A per gel) was applied to 
separate proteins until the blue dye front reached the bottom of the gel (~60 min).  
2.2.2. Detection of protein following SDS-PAGE 
 
 Following separation of proteins by SDS-PAGE the proteins must be stained to be 
visualised. Coomassie staining and silver staining were both used during the course of these 
studies.  
 Coomassie Staining To detect protein bands, SDS-polyacrylamide gels were stained 
by gentle agitatation in Coomassie staining solution (2.5 g Coomassie Brilliant Blue R-250 
dissolved in 45% (v/v) methanol, 10% (v/v) acetic acid in deionised water) for at least 20 min. 
After that, the gel was de-stained in 45% (v/v) methanol, 10% (v/v) acetic acid in deionised 
water, until clear bands were visible.  
 Silver Staining Silver staining was also used to visualize protein bands. After SDS-
PAGE, proteins were fixed in the gel using 50% (v/v) methanol, 5% (v/v) acetic acid in 
deionised water for 30 minutes. The gel was washed with 50% (v/v) methanol for 10 min 
followed by 10 min in deionised water, prior to incubation in 0.02% (w/v) sodium thiosulfate 
for 1 min. After 2 x 2 min washes with deionised water, the gel was bathed in  0.1% (w/v) 
silver nitrate for 20 minutes at 4 ºC followed by 2 x 2 min rinses with deionised water.  Gel 
bands were developed in 6% (w/v) sodium carbonate, 0.02% (w/v) sodium thiosulfate, 0.05% 
(v/v) formalin (35% formaldehyde in water) in deionised water. After 2 min washes with 
deionised water, the gel was placed into fix solution for 20 min. 
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2.2.3. Buffer Exchange 
 
 Most of the soluble protein samples were buffer exchanged prior to further 
sample processing or analysis. The protein solution was loaded into a 0.5 ml spin filter (5 
kDa molecular weight cut off). The spin filter was centrifuged at 14,000 x g, 4 ºC for 15 min. 
Fresh ammonium bicarbonate (50 mM) was added to the spin filter after each spin cycle. 
After 5 spin cycles, fresh ammonium bicarbonate (~200 μl of 50 mM) was added and the 
sample stored at -20 ºC until required. 
 
2.2.4. In-gel digestion 
 
 Gel pieces were de-stained prior to tryptic digestion. For Coomassie stained gels, 
100 μl of 50% (v/v) acetonitrile was added and the samples vortex mixed for 15 min. For 
silver stained gels, 100 μl of 15 mM potassium ferricyanide and 15 mM sodium thiosulfate 
were added and left to shake for 2 min. The gel pieces were washed with water until they 
were colourless. After de-staining, the gel pieces were dehydrated by addition of 100 μl of 
acetonitrile and allowed to dry completely in a fume hood. Dehydrated gels bands were 
rehydrated with 100 μl of trypsin at a concentration of 0.02 mg/ml in 50 mM ammonium 
bicarbonate and incubated at 37oC overnight. The peptides were extracted by adding 100 μl 
of acetonitrile. The supernatant was collected and the acetonitrile was then removed by 
speed-vac. The samples were stored at -20 ºC prior to mass spectrometric analysis. 
 
2.2.5. In-solution digestion 
 
Proteins were resuspended in 50 μl of 50 mM ammonium bicarbonate (pH 8). To 
reduce cystine to cysteine residues 5 mM dithiothreitol (DTT) was added and the samples 
incubated for 15 min at 60 ºC. The protein solution was cooled to room temperature. The 
sulfhydryl group of the reduced cysteine residues was alkylated by addition of 20 mM 
iodoacetamide and incubated at room temperature in the dark for 40 min. Excess 
iodoacetamide was quenched with the addition of DTT to a final concentration of 10 mM. 
Trypsin was added at a ratio of 1/50 (w/w) and incubated at 37 ºC overnight. The sample 
was collected and stored at -20 ºC prior to mass spectrometric analysis. 
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2.2.6. On-bead digestion 
 
 Biotinylated proteins bound to streptavidin beads were resuspended in 100 μl of 
trypsin (0.02 mg/ml) in 50 mM ammonium bicarbonate and incubated at 37oC overnight with 
shaking. The supernatant was collected and stored at -20 ºC prior to mass spectrometric 
analysis.  
 
2.2.7. Desalting 
 
 To decrease contamination and increase the sensitivity of mass spectrometric 
analysis, the proteins and peptides containing high concentrations of salt were desalted prior 
to MS analysis. 
 To desalt protein solutions, a C4 trap was used. The macro trap capacity was 200 
µg and the micro trap capacity was 20 µg. The trap was cleaned before use with 200 µl of 
acetonitrile, then equilibrated with 500 µl of 0.1% (v/v) formic acid. The protein sample (20-
200 µl) was loaded and salts washed away with 500 µl of 0.1% (v/v) formic acid. Finally, the 
peptides were eluted using 100 µl of 0.1% (v/v) formic acid in 80% (v/v) acetonitrile. 
 To desalt peptide solutions, a C18 trap and C18 ZipTipsTM were used. The macro 
trap capacity was 200 µg and the micro trap capacity was 20 µg and ZipTipsTM capacity was 
2 µg. The trap was cleaned before use with 200 µl of acetonitrile, then equilibrated with 500 
µl of 0.1% (v/v) formic acid. The protein sample (20-200 µl) was loaded and salts washed 
away with 500 µl of 0.1% formic acid. Finally, the peptides were eluted using 0.1% formic 
acid in 80% (v/v) acetonitrile. The C18 ZipTipsTM were used to desalt small volumes of 
peptides. The tip was rehydrated before use with 10 cycles of 10 μl of acetonitrile (1 cycle is 
an aspiration and dispensing) then equilibrated with 10 cycles of 10 μl of 0.1% (v/v) 
trifluoroacetic acid. The peptide sample was loaded using 20 cycles of 10 μl and salts were 
washed away with 10 cycles of 10 μl of 0.1% (v/v) trifluoroacetic acid. Finally, the peptides 
were eluted using 80% acetonitrile 0.1% (v/v) trifluoroacetic acid into a clean Eppendorf 
tube. When samples were to be subjected to electrospray analysis, 0.1% (v/v) formic acid 
was used instead of 0.1% (v/v) trifluoroacetic acid. 
 
2.2.8. Biotinylated peptide enrichment 
 
Avidin affinity columns were used to specifically enrich biotinylated peptides. 
Streptavidin HP Spintrap cap was broken off and centrifuged to remove the storage buffer. 
To equilibrate the spin column, 400 μl of 150 mM ammonium chloride in 10 mM ammonium 
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phosphate was added and centrifuged (150 g for 1 min). This step was performed 3 times. 
The biotinylated peptides (200 μl) were loaded onto the spin column and mixed end-over-
end for 60 min at room temperature. The spin column was centrifuged (150 g for 1 min) to 
wash out unbound peptides. 50 mM ammonium phosphate (400 μl) was added and 
centrifuged as above to wash the column. This step was performed 5 times followed by 
washing with 5 x 400 μl of MilliQ water. Biotinylated peptides that were bound to the 
streptavidin beads were eluted with 200 μl of 1 mM biotin in 70% (v/v) acetonitrile, 5% (v/v) 
formic acid. Biotinylated peptides were then dried down using a speed vacuum and 
resuspended in 500 μl of 10 mM potassium phosphate buffer (pH 3) in 25% (v/v) acetonitrile 
prior to removal of the biotin by cation exchange chromatography.  
 
2.2.9. Sample clean up with strong cation exchange  
 
The cation exchange cartridge (20 x 2.3 mm) was used to clean up enriched 
samples. To equilibrate the cartridge, 2 ml of 10 mM potassium phosphate buffer (pH 3) in 
25% (v/v) acetonitrile was injected (~1 drop/second) and diverted to waste. The 
resuspended biotinylated peptides were slowly loaded into the cartridge and the column 
washed with 1 ml of 10 mM potassium phosphate buffer (pH 3) in 25% (v/v) acetonitrile. 
Biotinylated peptides that were bound to the resin were eluted with 500 μl of 350 mM 
potassium chloride, 10 mM potassium phosphate buffer (pH 3) in 25% (v/v) acetonitrile. 
Biotinylated peptides were then dried down using a speed vacuum and resuspended in 0.1% 
(v/v) formic acid prior to desalting (2.2.7) and mass spectrometric analysis. 
 
2.2.10.  Isobaric tag for relative and absolute quantification (iTRAQTM) 
 
  The 4-plex iTRAQTM reagent, capable of quantifying up to four samples in 
one experiment, was used for all the studies detailed in this thesis. Samples (5 to 100 μg of 
protein) were dissolved in 20 μl of 0.5 M triethylammonium bicarbonate (pH 8.5) and 1 μl of 
2% (w/v) SDS. Samples were reduced using 2 μl of 50 mM tris-2-carboxyethyl phosphine 
and incubated at 60 oC for 1 h. The reduced cysteine residues were blocked using 1 μl of 
200 mM methylmethane thiosulfate and incubated at room temperature for 10 min. Trypsin 
was added at a ratio of 1/50 (w/w) and incubated at 37 ºC overnight. Each peptide mixture 
was separately labelled with the required iTRAQTM reagent in 70 μl of HPLC grade ethanol. 
The appropriate amount of each of the labelled samples were transferred into a single tube 
and mixed prior to mass spectrometric analysis. 
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2.2.11. Strong cation exchange chromatography (SCX) 
 
 Tryptic peptides were fractionated by off-line strong cation exchange 
chromatography using a polysulfoethyl column (PolyLC, MD, USA). Chromatographic 
analyses were performed on an Ultimate 3000 (Dionex, Surrey, UK) consisting of a solvent 
degasser, a pump, a column thermostat and a multi-wavelength UV–Vis detector for 
detection at both wavelengths 214 and 280 nm. Detection at 214 and 280 nm are for 
detecting peptide bonds and the three aromatic amino acids (tyrosine, phenylalanine and 
tryptophan), respectively. Data acquisition and analysis were performed using the 
Chromeleon chromatographic data software. Twenty fractions were typically collected over a 
30 min linear gradient from 100% A, 0% B to 10% A, 90% B using the following mobile 
phases: solution A, 20% (v/v) acetonitrile, 0.1% (v/v) formic acid; solution B, 20% (v/v) 
acetonitrile, 0.1% (v/v) formic acid, 1 M potassium chloride. All fractions were dried by 
vacuum centrifugation and stored at –20 oC. 
 
2.2.12. nESI-MS/MS analysis 
 
Samples were dissolved in 50% (v/v) acetonitrile and 1% (v/v) formic acid. The ToF 
mass analyser was calibrated at the beginning of every analysis with the fragment ions 
resulting from CID of the doubly protonated [Glu1]-fibrinopeptide B (Glu-Fib). Metal coated 
borosilicate capillaries for offline nanoelectrospray were used to produced a stable spray of 
10 to 40 nL/min. Analyses were carried out using a QToF Global (Waters, Manchester, UK). 
The capillary potential was held between 1.5 and 2 kV, and the cone was at 100 V. Source 
temperature was 85oC. Accelerator potential was 200 V Microchannel plate detector (MCP) 
was at 2300 V.  Peptide and protein mass spectra were accumulated for at least 1 min under 
the control of MassLynx software (Micromass). Protein spectra were processed using the 
maximum entropy approach. For tandem MS with product ion analysis, collisional activation 
of selected ions in tandem MS used argon as the collision gas at a recorded collision cell 
pressure of 1–3 millibar. The collision offset voltage was 30 eV. Spectra were accumulated 
for at least 1 min. 
 
2.2.13. ESI-LC-MS/MS analysis 
 
 A QToF Global (Waters, Manchester, UK) and a HCT ultra with ETD 
capabilities (Bruker, Coventry, UK) were used to analysed protein digests; both were 
coupled to an Ultimate 3000 capillary LC system (Dionex, Surrey, UK). The Ultimate 3000 
consisted of a 75 µm 15 cm reversed phase liquid chromatography capillary column (LC 
Packings, CA, USA), solvent degassers, a loading pump, an analytical pump, a column 
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thermostat set to 30 ºC to maintain a constant temperature and a UV–Vis detector to 
generate  a chromatogram of absorbance at 214 nm, along with the mass spectrometric data. 
Solution A consisted of 2% (v/v) acetonitrile, 0.1% (v/v) formic acid in HPLC grade water. 
Solution B consisted of 0.1% (v/v) formic acid in HPLC grade acetonitrile. The 58 min 
gradient started with 2% B and increased to 10% over 10 min. B was further increase to 40% 
over 45 min, ramped rapidly to 95% over 1 min and the column was washed for 4 min with 
95% B. After that, the gradient was reduced rapidly to 2% B for 8 min. The column was then 
ready for binding and chromatography of the next sample. The analysis was carried out 
using Chromeleon chromatographic data software. 
 
2.2.13.1. LC-MS and LC-MS/MS analyses using a QToF Global instrument 
 
To perform LC-MS and LC-MS/MS, using a QToF Global instrument, the the digestion 
mixture was acidified to 0.1% (v/v) formic acid, injected into an Ultimate 3000 capillary LC 
system via a FAMOS autosampler. The separation was done at a flow rate of 200 nl/min. At 
this flow rate, column pressure was 90 bar, master pressure was 140 bar and loading 
pressure was 58 bar. The eluent was sprayed from a distal-coated fused silica Picotip 
emitter using a capillary voltage of 22 to 28 kV into the Z-sprayTM nano-electrospray source 
of the QToF Global.  The cone was at 100 V. Source temperature was 85oC. Microchannel 
plates detector (MCP) was 2300 V.  Data were acquired using MassLynxTM version 4.0 
(Waters, Manchester, UK). The survey scan mode covered the mass range of m/z 400-2000. 
Three most abundant precursors were selected to fragment for 3 s. The collision offset was 
determined within the collision energy profile, where collision offset values are entered for 
ions based on their m/z and charge. This value was typically between 25-40 V for doubly, 
triply and quadruply charged ions with m/z of 400-2000. The MS/MS spectra covered the 
mass range of m/z 50-1500. 
 
2.2.13.2. LC-MS and LC-MS/MS analyses using a high capacity ion trap (HCT) with CID 
and ETD 
 
 To analyse LC-MS and LC-MS/MS analyses using a high capacity ion trap (HCT), 
the instrument was calibrated once every 2 months using the Agilent ESI tuning mix, which 
generates singly charged molecular ions at m/z 118, 322, 622, 922, 1522, and 2122. The 
peptides were separated using the LC system at a flow rate of 300 nl/min. At this flow rate, 
column pressure was 120 bar, master pressure was 200 bar and loading pressure 65 bar. 
The eluent was sprayed from a distal coated fused silica Picotip emitter using a capillary 
voltage of 1400-2000 V into the nano-electrospray source of the HCT.  Data were acquired 
using HyStarTM version 3.2.37 which integrated EsquireControl version 6.2 (for the control of 
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the HCT) and Chromeleon version 6.8. The standard enhanced scan mode was set and the 
m/z range was m/z 200-3000 with a speed of 8100 Th/s. Dry gas temperature was 150 ºC 
and dry gas flowwas 6 L/min. Ions were accumulated in the trap until the ion charge count 
(ICC) reached 20000 with a maximum accumulation time of 200 ms. CID/ETD was used to 
generated MS/MS spectra automatically choosing the top two most intense ions for 
fragmentation using CID and then ETD for each precursor ion. The ETD source temperature 
was set to 60 ºC with an ionisation energy of 80 eV and an emission current of 3 μA. 
 
2.2.14. MALDI-ToF analysis 
 
 Samples were dissolved in 0.1% (v/v) trifluoroacetic acid, 50% (v/v) acetonitrile then 
1 μl of the sample solution was spotted onto a MTP 384 polished or ground steel target (384-
well microtiterplate) followed by 1 µl of matrix and allowed to dry. The matrix for peptide 
analysis was a fully saturated solution of alpha-cyano-4-hydroxycinnamic acid (α-cyano) 
dissolved in 50% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid. The matrix for protein 
analysis was a fully saturated solution of sinapinic acid dissolved in 50% (v/v) acetonitrile 
and 0.1% (v/v) trifluoroacetic acid. MALDI-ToF and MALDI-ToF/ToF experiments were 
carried out on a Bruker Ultraflex IITM (Bruker). The Ultraflex IITM consists of gridless ion 
source, a nitrogen laser with a wavelength of 337 nm and LIFTTM for MS/MS fragmentation. 
Data were acquired and processed using FlexControlTM version 3.0 and Flexanalysis 
software (both Bruker Daltonik). The instrument was calibrated at the beginning of each 
analysis with QCAL105 standard peptides for peptide analysis and Protein Standard II (Bruker 
Daltonics) for protein analysis. Data were acquired by firing the laser at a frequency of 200 
Hz; 200 laser shots at each site were accumulated until 1000-2000 shots were used to 
obtain a mass spectrum. The reflectron detector voltage was 1680 V and the pulsed ion 
extraction was set to 10 ns. All analyses were carried out in positive mode. Peptide spectra 
were acquired over the range m/z 800-4000 in reflectron mode. Protein spectra were 
acquired over the range m/z 10,000-80,000 in linear mode. 
 
2.2.15. FT-ICR analysis 
 
 Samples were dissolved in 0.1% (v/v) formic acid, 50% (v/v) acetonitrile. All FT-ICR 
experiments were performed on a 9.4 T FT-ICR mass spectrometer (Apex IIITM, Bruker 
Daltonics Billerica, MA) with an Apollo electrospray source. Data acquisition was done using 
XmassTM software version 6.01. The isolated precursor ion was fragmented by infrared 
multiphoton dissociation (IRMPD) using a Synrad 48 series IR laser (λ=1060x103 nm). Each 
IRMPD spectrum was collected from 50 scans for the IRMPD spectra and 20 scans for 
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isolation optimisation using 512 data points per scan. The spectra were used to study the 
isotope distributions of (R)-lacosamide analogue fragment ions. 
 
2.2.16. Data analysis 
 
 Q-ToF instruments: The LC-MS/MS data file was converted into a peak list file (.pkl) 
using Proteinlynx (MassLynx 4.0, Waters). The .pkl file contained m/z of precursor ion, m/z 
of corresponding fragment ions, signal intensities and charge state. The file was then 
searched against the in-house Mascot103 version 2.2 (Matrix Science Ltd, London, UK). 
 Ion Trap Instrument: The LC-MS/MS data file was converted into a smoothed and 
centroided mascot generic file (.mgf) using DataAnalysisTM software, version 3.4. The .mgf 
file contained m/z of precursor ion, m/z of corresponding fragment ions, signal intensities and 
charge state. The file was then searched against the in-house Mascot103 version 2.2. 
 Criteria for selecting a peptide: The Swiss-Prot database (version 53.0), contains 
517802 sequence entries, was used to search all MS/MS data. It is a high quality protein 
database; sequences are non-redundant. Mus musculus was set for mouse samples and 
Rattus norvegicus was set for rat samples. A decoy algorithm was used to estimate the 
number of false positives. Missed cleavages were set to 2 with peptide tolerance set to 100 
ppm and tandem MS tolerance set to 0.3 Da. Variable modifications were set to include 
methionine oxidation. Only peptides identified above 95% confidence are reported in this 
thesis. Each identified peptide was searched against BLAST (Basic Local Alignment Search 
Tool) for considering isoforms of proteins (www.ncbi.nlm.nih.gov/BLAST).  
The mass spectra of the proteins or peptides containing the biotinyl (R)-lacosamide 
analogue were interpreted manually using masses expected for the digested protein from 
Protein Prospector (http://prospector.ucsf.edu/). 
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CHAPTER 3 
Results I 
Characterisation of conjugates of biotinyl (R)-
lacosamide analogue A by mass spectrometry 
 
3.1. Introduction 
 
 To enable the identification of candidate target proteins of the anti-epileptic drug 
lacosamide, a biotinyl (R)-lacosamide analogue was designed.  However, no MS information 
of the biotinyl (R)-lacosamide analogue A has been reported. Preliminary experiments were 
therefore designed to characterise this biotinyl (R)-lacosamide analogue A. The analogue A 
was conjugated separately to an amino acid, a peptide and a protein, to define the MS 
properties of the analogue when attached to species of increasing complexity.  
 
3.2. Modification of an amino acid by biotinyl (R)-lacosamide analogue A. 
 
Lysine was chosen to be a model for the amino acid level study because it is an 
expected target of isothiocyanate (the affinity bait). Acetylation was used to protect the N-
terminal group of lysine after which the side chain was modified by the biotinyl (R)-
lacosamide analogue A (Figure 3.1).    
 
Figure 3.1 Structure of biotinyl (R)-lacosamide analogue A conjugated to N-acetyl 
lysine. 
  
The chemical formula for biotinyl (R)-lacosamide analogue A conjugated to N-acetyl lysine is 
C43H67N11O11S2 and the molecular weight is 977.5 Da. This modified lysine residue was 
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analysed by both MALDI and ESI. Both techniques were able to ionize and produce mass 
spectra of singly protonated modified lysine at m/z 978.5. This species was fragmented by 
CID to obtain characteristic product ion mass spectra (Figure 3.2). To understand more 
about the fragmentation of analogue A, the FT ICR mass spectrometer was used to obtain 
extremely accurate data at high resolution. This was then compared with the predicted 
isotope distribution of dominant characteristic fragment ions of analyte A of defined 
elemental composition (Figure 3.3).  MS Fragmenter, software for predicting MS 
fragmentation of small organic molecules (Waters, Manchester, UK), was used to review a 
list of possible structures of the characteristic fragmented ions. Masses and isotopic 
abundance distributions calculated from predicted structures were compared with data from 
the FT-ICR mass spectrometer (Figure 3.4).  
 
  
 
Figure 3.2 CID product MS spectra of singly protonated modified N-acetyl lysine at m/z 
978.5 generated by MALDI-ToF (A) and ESI-QToF (B). 
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Figure 3.3 IRMPD product MS spectra of singly protonated modified N-acetyl lysine at 
m/z 978.5 generated by FT-ICR. 
 
 
 
Figure 3.4 Comparing isotopic distributions between FT-ICR data and predicted 
elemental composition (A) Isotopic distribution of m/z 776.3 generated from FT-ICR. (B) 
Isotopic distribution of m/z 776.3 predicted from C34H49N9O8S2 
 
 
 
 
 
 
 
                            Results I Chapter 3 
  58 
The chosen structures of dominant fragmented ions were the structures, which 
demonstrated least error between their predicted and observed mass and the correct 
isotopic distribution (Table 3.1). The structure of m/z 776.3 was singly protonated biotinyl 
(R)-lacosamide analogue A. The lower m/z fragmented ions were fragmented from the 
higher m/z fragmented ions. Most of fragmentations occurred on C-N bonds.
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Table 3.1 Predicted element composition and structure of fragment ions derived from biotinyl (R)-lacosamide analogue A conjugated to N-acetyl 
lysine 
 
% Relative abundance 
of 2nd isotope peak 
% Relative abundance  
of 3rd isotope peak 
Predicted m/z 
(1st isotope peak) 
Observed m/z 
(1st isotope peak) 
Error (ppm) 
(1st isotope peak) 
Predicted Observed Predicted Observed 
Structure 
776.3218 776.3213 0.6 37 37 9 11 
 
734.3654 734.3653 0.1 36 37 6 7 
 
629.3075 629.3072 0.5 28 27 5 7 
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Table 3.1 (cont.) Predicted element composition and structure of fragment ions derived from biotinyl (R)-lacosamide analogue A conjugated to N-
acetyl lysine 
 
% Relative abundance 
of 2nd isotope peak 
% Relative abundance  
of 3rd isotope peak 
Predicted m/z 
(1st isotope peak) 
Observed m/z 
(1st isotope peak) 
Error (ppm) 
(1st isotope peak) 
Predicted Observed Predicted Observed 
Structure 
612.2810 612.2817 -1.1 28 29 5 - 
 
501.2490 501.2489 0.2 23 24 5 - 
 
483.2384 483.2384 0.0 23 20 5 3 
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Table 3.1 (cont.) Predicted element composition and structure of fragment ions derived from biotinyl (R)-lacosamide analogue A conjugated to N-
acetyl lysine 
 
% Relative abundance 
of 2nd isotope peak 
% Relative abundance  
of 3rd isotope peak 
Predicted m/z 
(1st isotope peak) 
Observed m/z 
(1st isotope peak) 
Error (ppm) 
(1st isotope peak) 
Predicted Observed Predicted Observed 
Structure 
455.2323 455.2318 1.1 23 23 5 - 
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3.3. Modification of a peptide by biotinyl (R)-lacosamide analogue A  
 
Neurotensin peptide was conjugated to the biotinyl (R)-lacosamide analogue A and 
used as a model for this peptide level study (Figure 3.5). This compound was analysed by 
both MALDI-ToF mass spectrometry (in both linear and reflectron mode) (Figure 3.6) and by 
ESI on a Q-ToF mass spectrometer (Figure 3.7). 
 
 
Figure 3.5 Structure of biotinyl (R)-lacosamide analogue A conjugated to neurotensin. 
 
Singly protonated unmodified neurotensin could be observed from both unmodified and 
modified samples in reflectron mode at m/z 1672.9. However, singly protonated modified 
neurotensin could be observed only in linear mode. Based on this evidence, it was 
concluded that singly protonated modified neurotensin was fragmenting after the source, 
most likely undergoing metastable decomposition in the field-free region of the flight tube 
(Figure 1.16). Thus, in reflectron mode, all the singly protonated modified neurotensin ions 
fragment after leaving the source. The ions which fragment between the source and detector 
are designated post source decay (PSD) ions. The fragmented ions have different m/z 
values but have the same velocity and reach the reflectron at the same time. The reflectron 
separates these PSD ions of different m/z as they have different kinetic energies, and each 
fragmented m/z arrives at the reflectron detector at a different time. Therefore, none of the 
peaks could be detected at m/z 2448.6 which is the singly protonated modified neurotensin. 
In linear mode, fragmentation of ions outside the source does not affect the arrival time at 
the detector, so that ions may be detected with a time-of-flight characteristic of the precursor 
ions regardless of fragmentation during flight.  Therefore, m/z 2448.6 could be detected in 
linear mode. The conclusion was that the protonated form of the putative modified 
neurotensin was unstable, explaining the failure to observe it at its true m/z.  MALDI-ToF is 
therefore not a choice for analysis of the biotinyl lacosamide analogue A attached on 
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peptide. ESI was then used to analyse this compound using a Q-ToF mass spectrometer 
(Figure 3.7). 
 The doubly and triply protonated unmodified neurotensin could be observed 
from the unmodified and modified samples at m/z 836.9 and 558.2 respectively. The doubly 
and triply protonated modified neurotensin could only be observed from modified samples at 
m/z 1224.4 and 816.7, respectively.  ESI is therefore a more suitable method of ionisation to 
use in the analysis of the biotinyl (R)-lacosamide analogue A attached to a peptide.  
 
 
 
Figure 3.6 MALDI-ToF mass spectra of the biotinyl (R)-lacosamide analogue A and its 
conjugate with neurotensin. (A) Mass spectrum of unmodified neurotensin. (B) Mass 
spectrum of modified neurotensin analysed in reflectron mode. (C) Mass spectrum of 
modified neurotensin analysed in linear mode. [M+H]+ and [M*+H]+ refer to singly protonated 
unmodified neurotensin and modified neurotensin, respectively. 
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Figure 3.7 ESI-QToF mass spectra of the biotinyl (R)-lacosamide analogue A and its 
conjugate with neurotensin. (A) Mass spectrum of unmodified neurotensin. (B) Mass 
spectrum of modified neurotensin. [M+2H]2+ and [M+3H]3+ refer to doubly and triply 
protonated unmodified neurotensin, respectively. [M*+2H]2+ and [M*+3H]3+ refer to doubly 
and triply protonated modified neurotensin, respectively. 
 
3.4. Modification of a protein by biotinyl (R)-lacosamide analogue A 
 
 Enolase was conjugated to the biotinyl (R)-lacosamide analogue A and used as 
a model for protein level study (Figure 3.8).  The modified protein was analysed by mass 
spectrometry both as an intact protein and following tryptic digestion. 
 
Figure 3.8 Structure of biotinyl (R)-lacosamide analogue A conjugated to enolase. 
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3.4.1. Intact protein analysis 
 
Unmodified and modified intact enolase were analysed by MALDI-ToF MS in linear 
mode (Figure 3.9).  Singly protonated intact unmodified enolase could be observed in both 
MALDI mass spectra (Figure 3.10). However, the peak representing intact modified enolase 
could not be observed in the MALDI-ToF mass spectrum. In both peptide and protein cases, 
there is evidence for the instability of the ionised modified species in the gas phase. A 
second experiment was therefore performed, using ESI to analyse the biotinyl (R)-
lacosamide analogue A attached on intact enolase (Figure 3.10). 
 
 
 
Figure 3.9 MALDI-ToF mass spectrum of the biotinyl (R)-lacosamide analogue A and 
its conjugate with enolase. (A) Mass spectrum of unmodified enolase. (B) Mass spectrum 
of modified enolase. 
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Figure 3.10 ESI-QToF deconvoluted mass spectrum of the biotinyl (R)-lacosamide 
analogue A conjugate with enolase. M and M* refer to unmodified enolase and modified 
enolase, respectively. 
 
Singly protonated unmodified enolase and modified enolase could be observed from the 
ESI-QToF mass spectrum. This result also corresponded to the peptide level analysis which 
demonstrated that ESI was able to ionize and provide m/z information on the modified 
species. Therefore, analysis of the tryptic peptides of modified enolase was carried out by 
ESI-QToF. 
 
3.4.2. Tryptic digest analysis 
 
The intact modified enolase was digested using trypsin and subjected to LC-MS/MS. 
Doubly and triply protonated enolase peptides were fragmented by CID. The results (Table 
3.2) showed four peptides that were derived from the biotinyl lacosamide analogue A.   
 
Table 3.2 Modified enolase peptides identified by LC-MS/MS. * denotes modification 
 
Observed Charge Sequence 
713.1 2 DGDK*SK 
825.2 2 IATAIEK*K 
896.7 3 TAGIQIVADDLTVTNPK*R 
923.0 3 GVLHAVK*NVNDVIAPAFVK 
 
The additional mass of the modified peptides was 776 Da.  CID tandem mass spectra of 
modified enolase peptides contained characteristic fragmented ions of analogue A similar to 
the modified N-acetyl lysine (Figure 3.11). Using CID, characteristic fragment ions of the 
analogue were much more abundant than b and y ions derived from the modified peptide. All 
sequence-related fragment ions demonstrated loss of the lacosamide analogue; accordingly, 
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though the sequence of the modified peptide is fully defined, all MS/MS data were 
interpreted manually to confirm the peptide sequence. Because of the preferential loss of the 
lacosamide analogue from the peptide during CID, there is no direct mass spectrometric 
evidence enabling identification of the site of modification. However, a missed cleavage on a 
lysine residue was detected in all of the modified peptides, which is significant because 
lysine is the target of isothiocyanate 106. Therefore, missed cleaved lysine residues could be 
assumed as the modification sites. This evidence occurred on every modified enolase 
peptide observed (Table 3.1).  
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Figure 3.11 CID product ion mass  spectra (A) singly protonated modified N-acetyl lysine (B) doubly protonated enolase peptide (IATAIEKK) at m/z 825.2. 
[M+H]+ refers to singly protonated unmodified IATAIEKK.
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3.5. Discussion 
 
The experiments in this chapter demonstrate the mass spectrometric 
characterisation of the biotinyl (R)-lacosamide analogue A bound to an amino acid, a peptide 
or a protein.  Protonated modified peptide and protein showed evidence for the instability of 
the ionised modified species in the gas phase. Using MALDI for ionisation, excess energy is 
transferred to the analyte resulted in decomposition of intact analyte ion and loss of the 
modification prior to mass analysis. ESI is therefore more suitable to use in the analysis of 
modified peptides and proteins.  All subsequent experiments described thus make use of 
ESI to ionize samples. CID fragmentation technique is able to provide peptide sequence 
information. However, as the analogue A preferentially cleaves from the peptide, it is not 
possible to identify the modification site directly. Prediction of the site of modification can be 
done by observation of the presence and localization of lysine and cysteine residues in the 
sequence. 
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CHAPTER 4 
Results II 
Identification of candidate target proteins using 
biotinyl (R)-lacosamide analogue A 
 
4.1. Introduction 
 
This chapter focuses on developing techniques to identify candidate target proteins 
of lacosamide using the biotinyl (R)-lacosamide analogue A.  The chemical reporter of (R)-
lacosamide analogue A is isothiocyanate (Figure 4.1).  
 
Figure 4.1 The structure of (R)-lacosamide analogue A. 
 
Fractionation techniques such as gel electrophoresis and strong cation exchange 
chromatography were introduced to improve the number of protein identifications.  
 
4.2. Identification of candidate target proteins by in-gel digestion  
 
To identify candidate target proteins of lacosamide, mouse brain lysates in 50 mM 
HEPES pH 7.4 (w/v) were treated with (R)-lacosamide analogue A and incubated for 12-16h 
rotating at room temperature. The lysate mixture was reacted with an appropriate biotin 
probe and 1h at room temperature. The biotinylated proteins were captured with streptavidin 
beads, the beads were stringently washed to remove background proteins adsorbed on the 
resin with 1 ml of 50 mM HEPES, 150 mM NaCl and then the protein adducts released by 
heating in SDS loading buffer for 15 min at 95°C. The eluted samples were separated by 
SDS-PAGE. Negative controls, where brain lysates were either left untreated or treated with 
(R)-lacosamide analogue A without the CR group, were used to assess the specificity of 
protein binding and processed concurrently with the biotinyl (R)-lacosamide analogue A 
experiment.  Twelve bands from the biotinyl (R)-lacosamide analogue A experiment and 
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negative control lanes were cut. The procedures described above were undertaken by Steve 
Cotton in the laboratory of Prof. Harold Kohn at the University of North Carolina.  The gel 
samples without buffer were then shipped in ambient temperature to Manchester for protein 
identification by in-gel digestion (Figure 4.2). 
 
 
Figure 4.2 Silver stained gels of mouse brain lysate after ligand-based affinity 
purification. Lanes labelled 1, 2, 3, and 4 indicate molecular marker, mouse brain lysate 
after enriched by biotinyl (R)-lacosamide analogue A, enriched by(R)-lacosamide analogue A 
without CR group (control), enriched by no drug (control), respectively. Figure provided by 
Steve Cotton from University of North Carolina. 
 
In-gel digestion samples were analysed by a reversed phase LC-MS/MS using a Q-ToF 
instrument. Peak lists were generated from the .raw data files and searched using the 
Mascot search algorithm against the Swiss-Prot database version 56.0, with the organism 
specified as a Mus musculus (Table 4.1). Decoy algorithm was set to estimate the number of 
false positives. According to the results, ten mouse proteins were identified as candidate 
target proteins of lacosamide from the mouse brain lysate after affinity enrichment of biotinyl 
(R)-lacosamide analogue A bound sample. Actin was reported as a candidate target based 
on only one peptide identification. However, its ion score was above 95% confidence over 
score and MS/MS spectrum was acceptable (Figure 4.3). Therefore, actin was also reported 
in the Table 4.1.  
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Figure 4.3 CID product ion spectrum of doubly protonated actin peptide 
(SYELPDGQVITIGNER) at m/z 896.01.  
 
In this experiment, the false positive rate was estimated by decoy algorithm. It was estimated 
at 3% approximately, which was acceptable because it was less than 5%, the maximum 
acceptable rate for general proteomics studies. None of the candidate target proteins could 
be detected in the negative controls. Only keratin, type I cytoskeletal 10 was identified, which 
is a common contaminant observed in these types of studies. Therefore, the protocol 
showed potential to identify candidate targets. However, the amount of some candidate 
target proteins is probably so small that they can not be visualized by silver staining and will 
not be identified using this experimental strategy. Therefore, the protocol was developed to 
perform on-bead digestion of enriched proteins rather than in-gel digestion of silver stained 
proteins.  
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Table 4.1 LC-MS/MS Mascot results of in-gel tryptic digestions of mouse brain lysate after treatment with biotinyl (R)-lacosamide analogue A and 
controls, with subsequent enrichment using streptavidin beads.  Significant peptide score was approximately 30 (p<0.05). False discovery rate was 
approximately 3.0%  
 
Sample Gel band Protein identification 
Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
Treatment with (R)-
biotinyl lacosamide A 1 ADP/ATP translocase 1 428.72 -58 36 0.011 GNLANVIR 1,2,4 
   502.74 -64 48 0.042 QIFLGGVDR 1 
   610.28 -72 81 6.3e-07 DFLAGGIAAAVSK 1 
  14-3-3 protein zeta/delta 454.23 -63 31 0.034 NLLSVAYK 
zeta/delta, sigma 
epsilon, eta, gamma, 
beta/alpha, theta 
   665.79 -77 32 0.031 FLIPNASQPESK zeta/delta 
   774.78 -81 54 0.0015 SVTEQGAELSNEER zeta/delta 
 2 - -  - - - - 
 3 Glyceraldehyde-3-phosphate dehydrogenase 415.18 -78 32 0.078 QASEGPLK - 
   685.31 -81 35 0.015 GAAQNIIPASTGAAK - 
  Malate dehydrogenase mitochondrial precursor 496.72 -85 31 0.033 ANTFVAELK mitochondrial precursor 
   537.25 -69 48 0.0066 IQEAGTEVVK mitochondrial precursor 
 4 
Actin cytoplasmic 1, gamma-enteric 
smooth muscle, alpha cardiac muscle 
1, aortic smooth muscle or alpha 
skeletal muscle 
 
895.95 11 88 6.30E-08 SYELPDGQVITIGNER 
cytoplasmic 1, gamma-
enteric smooth muscle, alpha 
cardiac muscle 1, aortic 
smooth muscle, alpha 
skeletal muscle 
 
 5 Elongation factor 1 alpha 1, 2 457.76 -44 31 0.081 QTVAVGVIK alpha 1, 2 
   488.24 -63 39 0.0033 LPLQDVYK alpha 1, 2 
   513.27 -61 43 0.0021 IGGIGTVPVGR alpha 1, 2 
  Enolase alpha 352.67 -82 33 0.054 GVPLYR alpha, beta 
   383.65 -83 36 0.015 EIFDSR alpha 
   452.69 -81 37 0.0094 IEEELGSK alpha 
 6 ATP synthase subunit alpha 362.19 -85 33 0.044 APGIIPR subunit alpha 
   500.77 -39 33 0.031 VLSIGDGIAR subunit alpha 
   513.77 -45 39 0.0047 AVDSLVPIGR subunit alpha 
   788.34 -63 34 0.013 ILGADTSVDLEETGR subunit alpha 
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Table 4.1 (cont.) LC-MS/MS Mascot results of in-gel tryptic digestions of mouse brain lysate after treatment with biotinyl (R)-lacosamide analogue A 
and controls, with subsequent enrichment using streptavidin beads.  Significant peptide score was approximately 30 (p<0.05). False discovery rate was 
approximately 3.0%.  
 
Sample Gel band Protein identification 
Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
Treatment with (R)-
biotinyl lacosamide A 7 
Dihydropyrimidinase-related protein 
1 or 2 542.78 -64 39 0.0054 GSPLVVISQGK 1,2 
   662.34 -57 40 0.0044 QIGENLIVPGGVK 1,2 
  Histone 4 495.31 31 31 0.072 VFLENVIR 4 
   590.77 -63 34 0.042 ISGLIYEETR 4 
 8-12 - -  - - - - 
Treatment with 
lacosamide 
analogue A without 
CR group 
1-12 - -  - - - - 
No treatment 1-4 - -  - - - - 
 5 Keratin type I cytoskeletal 10 404.17 -62 32 0.040 LAADDFR type I cytoskeletal 10,13,14,15,16,17,18,19,24,28,40,42 
   583.26 -50 36 0.018 LENEIQTYR type I cytoskeletal 10 
   691.34 28 32 0.033 ALEESNYELEGK type I cytoskeletal 10 
 6 Keratin type I cytoskeletal 10 404.17 -62 32 0.040 LAADDFR type I cytoskeletal 10,13,14,15,16,17,18,19,24,28,40,42 
   691.34 28 32 0.033 ALEESNYELEGK type I cytoskeletal 10 
 7-12 - -  - - - - 
 
“ppm” refers to the difference between observed precursor ion mass and expected for the identified peptide. 
“Expectation value”  refers to the number of times that expect to obtain this score or better by chance. 
“ – “ means that no peptides were identified in the digest of this gel band. 
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4.3. Identification of candidate target proteins by on-bead digestion  
 
To identify candidate target proteins of lacosamide drug using on-bead digestion, the sample 
preparation was similar to the in-gel digestion but proteins were recovered from the 
streptavidin bead. Mouse brain lysate treated in the specific manner was provided by Steve 
Cotton from at the University of North Carolina.  After the biotinylated proteins were captured 
with streptavidin beads, the beads were stringently washed to remove background proteins 
adsorbed on the resin. Digestion buffer and trypsin were then added to the beads and 
incubated overnight. Negative control (no drug) was processed in the same way as the same 
as the biotinyl (R)-lacosamide analogue A experiment.  The on-bead digestion sample was 
analysed by a reversed phase LC-MS/MS using a Q-ToF instrument. Data analysis was 
processed the same as the in-gel digestion data (Table 4.2). Nineteen candidate target 
proteins were identified following on-bead digestion. Of these, nine was also identified in the 
in-gel digestion samples. However, actin identified in the previous in-gel digestion study was 
not reported under these conditions because the ion score was 24, lower than the 29 
significant peptide score (p<0.05). Eleven more candidate target proteins were identified 
(sodium/potassium-transporting ATPase subunit alpha 3, 14-3-3 protein gamma, 14-3-3 
protein sigma, ATP synthase subunit beta, creatine kinase B-type, fructose-bisphosphate 
aldolase A, syntaxin-binding protein 1, vesicle-fusing ATPase, enolase gamma, guanine 
nucleotide-binding protein G(o) subunit alpha and 2',3'-cyclic-nucleotide 3'-
phosphodiesterase). Three proteins were reported as the candidate targets based on only 
one peptide (creatine kinase B-type, syntaxin-binding protein 1 and vesicle-fusing ATPase). 
In this case, their MS/MS spectra were assessed manually and confidently identified these 
proteins as the candidate targets (Figure 4.4). No proteins could be identified in the negative 
control. In this experiment, the false positive rate was estimated at 2.5% approximately, 
which was acceptable because it was less than 5%, the maximum acceptable rate for 
general proteomics studies. 
However,  there was a problem associated with this method. Streptavidin used in the 
enrichment of the biotinylated lacosamide analogue was also digested by trypsin and yielded 
the most abundant peptides during the analysis.    During LC-tandem MS, a peptide was 
selected for fragmentation based on its ion signal intensity. Therefore, these high abundant 
streptavidin peptides were selected for fragmentation rather than peptides from mouse brain 
during LC-MS/MS analysis. To improve the detection of mouse brain peptides, strong cation 
exchange chromatography was introduced to separate on-bead digestion samples. 
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Figure 4.4 CID product ion spectra (A) Doubly protonated creatine kinase B-type  peptide (VLTPELYAELR) at m/z 652.36. (B) Doubly protonated syntaxin-
binding protein 1 peptide (VEQDLAMGTDAEGEK) at m/z 796.87. (C) Doubly protonated vesicle-fusing ATPase peptide (AENSSLNLIGK) at m/z 573.29.
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Table 4.2 LC-MS/MS Mascot results from LC-MS/MS analysis following CID of on-bead trypsin digestions of mouse brain lysate after enriched by 
biotinyl (R)-lacosamide analogue A. Significant peptide score was 29 (p<0.05). False discovery rate was approximately 2.5%. 
 
Protein identification Protein score Observed m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
Sodium/potassium-transporting ATPase subunit alpha 3 328 423.74 36 36 0.017  DLDDLKK subunit alpha 3 
  520.80 33 43 0.0022  GGQDNIPVLK subunit alpha 3 
  618.87 34 51 0.00035  LNIPVSQVNPR subunit alpha 2,3 
  810.30 30 73 2.60E-06  VDNSSLTGESEPQTR subunit alpha 1,2,3 
  906.44 36 35 0.015  QGAIVAVTGDGVNDSPALK subunit alpha 1,2,3,4 
  915.48 29 59 6.20E-05  GVGIISEGNETVEDIAAR subunit alpha 1,2,3 
  936.52 38 31 0.12  MQVNAEEVVVGDLVEIK subunit alpha 3 
ADP/ATP translocase 1 104 428.77 59 52 0.00027  TAVAPIER 1,2,4 
  610.37 65 52 0.00031  DFLAGGIAAAVSK 1 
14-3-3 protein zeta/delta 
138 
595.36 53 37 0.045  DSTLIMQLLR 
theta, beta/alpha, 
gamma, eta, epsilon, 
sigma, zeta/delta 
  774.89 47 50 0.00054  SVTEQGAELSNEER zeta/delta 
 
 
1101.59 42 51 0.00019 
 
TAFDEAIAELDTLSEESYKDST
LIMQLLR 
zeta/delta 
14-3-3 protein gamma 
113 
595.36 53 37 0.045  DSTLIMQLLR 
theta, beta/alpha, 
gamma, eta, epsilon, 
sigma, zeta/delta 
  452.27 37 39 0.008  VISSIEQK eta, gamma, beta/alpha, theta 
 
 
1101.23 23 37 0.0049 
 
TAFDDAIAELDTLNEDSYKDST
LIMQLLR 
gamma 
Dihydropyrimidinase-related protein 2 101 454.75 -11 33 0.026  VFNLYPR 2 
  662.41 46 36 0.012  QIGENLIVPGGVK 1,2 
  958.52 41 32 0.026 ISVGSDADLVIWDPDSVK 2 
ATP synthase subunit beta 95 801.44 51 34 0.041  VALVYGQMNEPPGAR subunit beta 
  961.51 32 61 3.80E-05 DQEGQDVLLFIDNIFR subunit beta 
Fructose-bisphosphate aldolase A 104 401.24 -12 34 0.029  ALQASALK A 
  554.31 41 38 0.0078  AAQEEYIKR A 
  745.84 -15 32 0.03  LQSIGTENTEENR A 
Enolase gamma 81 580.81 62 39 0.0078 IEEELGDEAR gamma 
  903.03 58 42 0.0043 AAVPSGASTGIYEALELR alpha, beta, gamma 
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Table 4.2 (cont.) LC-MS/MS Mascot results from LC-MS/MS analysis following CID of on-bead trypsin digestions of mouse brain lysate after 
enriched by biotinyl (R)-lacosamide analogue A. Significant peptide score was 29 (p<0.05). False discovery rate was approximately 2.5%. 
 
Protein identification Protein score Observed m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
Guanine nucleotide-binding protein G(o) subunit alpha 71 529.34 56 33 0.015  LLLLGAGESGK G(o), G(olf), G(k), G(t), G(i), G(s) subunit alpha 1 
  838.45 43 38 0.0074 IGAGDYQPTEQDILR G(o) subunit alpha 
2',3'-cyclic-nucleotide 3'-phosphodiesterase 72 523.93 -22 35 0.011 KAGQVFLEELGNHK - 
  628.85 57 37 0.0099 GGSQGEAVGELPR - 
Creatine kinase B-type 70 652.36 -10 70 0.0074 VLTPELYAELR B-type 
Syntaxin-binding protein 1 82 796.87 23 82 5.40E-06 VEQDLAMGTDAEGEK 1 
Vesicle-fusing ATPase 73 573.29 25 73 3.20E-06 AENSSLNLIGK - 
Glyceraldehyde-3-phosphate dehydrogenase 65 398.23 51 34 0.029  LTGMAFR - 
  890.41 17 31 0.032  LISWYDNEYGYSNR - 
Malate dehydrogenase mitochondrial precursor 68 496.76 14 36 0.017 ANTFVAELK mitochondrial precursor 
  537.32 56 32 0.019 IQEAGTEVVK mitochondrial precursor 
Elongation factor 1 alpha 1 or 2 69 457.81 55 33 0.077 QTVAVGVIK alpha 1, 2 
  488.28 21 36 0.016 LPLQDVYK alpha 1, 2 
Enolase alpha 110 383.68 -13 30 0.056 EIFDSR alpha 
  452.71 -28 38 0.0087 IEEELGSK alpha 
  903.03 58 42 0.0043 AAVPSGASTGIYEALELR alpha, beta, gamma 
ATP synthase subunit alpha 68 500.80 29 30 0.057 VLSIGDGIAR subunit alpha 
  513.77 -21 38 0.0079 AVDSLVPIGR subunit alpha 
Histone 4 67 495.27 -19 32 0.032  VFLENVIR 4 
  590.80 -12 35 0.021  ISGLIYEETR 4 
 
“ppm” refers to the difference between observed precursor ion mass and expected for the identified peptide. 
“Expectation value”  refers to the number of times that expect to obtain this score or better by chance. 
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4.4. Separating peptides from on-bead digestion using SCX   
 
To increase the resolving capability of the HPLC separation, two dimensional HPLC 
techniques were employed using a combination of strong cation exchange chromatography, 
where the peptides were separated based on their charge, followed by reversed phase liquid 
chromatography, which separates peptides based on their hydrophobicity.  For strong cation 
exchange chromatography, all 20 fractions were collected over a 30 min linear gradient 
using the following mobile phases: solution A, 20 % (v/v) acetonitrile, 0.1 % (v/v) formic acid; 
solution B, 20 % (v/v) acetonitrile, 0.1 % (v/v) formic acid, 1 M potassium chloride. This 
approach greatly reduces the complexity of the peptide mixture being analysed by the Q-ToF 
instrument at any one time. Data were processed in a similar manner to the previous 
experiments (Table 4.3). All proteins identified following the one-dimensional LC-MS/MS 
study were also identified by LC-MS/MS after two dimensional separation. Eight more 
candidate target proteins of lacosamide were additionally identified following two-
dimensional separation.  No proteins were identified from the control, similar to the previous 
experiment. SCX separation therefore improved the potential of identifying candidate target 
proteins. In this experiment, the false positive rate was estimated at 2.5% approximately, 
which was acceptable because it was less than 5%, the maximum acceptable rate for 
general proteomics studies. 
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Table 4.3 Mascot results from LC-MS/MS analysis of on-bead trypsin digested biotinyl (R)-lacosamide analogue A enriched mouse brain samples 
after SCX separation. Significant peptide score was 29 (p<0.05). False discovery rate was approximately 2.5% 
 
Protein identification Protein score 
Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
Sodium/potassium-transporting ATPase subunit alpha 3 499 495.82 46 32 0.057  LIFDNLKK subunit alpha 1,2,3,4 
  618.89 55 80 5.60E-07 LNIPVSQVNPR subunit alpha 2,3 
  634.87 23 37 0.011 NMVPQQALVIR subunit alpha 1,2,3,4 
  906.53 56 82 3.60E-07 QGAIVAVTGDGVNDSPALK subunit alpha 1,2,3 
  915.52 57 145 1.50E-13 GVGIISEGNETVEDIAAR subunit alpha 1,2,3 
  1116.45 -24 78 7.50E-07 TVNDLEDSYGQQWTYEQR subunit alpha 3 
  956.07 -38 45 0.001 EQPLDEEMKEAFQNAYLELGGLGER subunit alpha 3 
Glyceraldehyde-3-phosphate dehydrogenase 262 543.34 45 52 0.00037  LVINGKPITIFQER - 
  890.44 40 72 2.50E-06  LISWYDNEYGYSNR - 
  1146.01 -11 138 5.10E-13  WGEAGAEYVVESTGVFTTMEK - 
Sodium/potassium-transporting ATPase subunit alpha 1 346 495.82 46 32 0.057  LIFDNLKK subunit alpha 1,2,3,4 
  632.39 54 50 0.0018  LNIPVNQVNPR subunit alpha 1 
  634.87 23 37 0.011  NMVPQQALVIR subunit alpha 1,2,3,4 
  906.53 56 82 3.60E-07  QGAIVAVTGDGVNDSPALK subunit alpha 1,2,3 
  915.52 57 145 1.50E-13  GVGIISEGNETVEDIAAR subunit alpha 1,2,3 
Vesicle-fusing ATPase 138 492.25 21 36 0.011  MIGFSETAK - 
  569.29 28 44 0.002  YVGESEANIR - 
  604.29 24 58 9.00E-05  LFADAEEEQR - 
Fructose-bisphosphate aldolase C 167 826.99 33 76 1.90E-06  TPSALAILENANVLAR c 
  1150.08 -34 91 3.60E-08  GVVPLAGTDGETTTQGLDGLLER c 
ATP synthase subunit alpha 272 500.79 11 32 0.037  VLSIGDGIAR subunit alpha 
  513.67 -24 56 0.00031  AVDSLVPIGR subunit alpha 
  644.38 46 80 6.30E-07  HALIIYDDLSK subunit alpha 
  812.94 -12 104 0.00066  TGAIVDVPVGEELLGR subunit alpha 
Hemoglobin subunit beta-1 151 637.89 48 35 0.037  LLVVYPWTQR subunit beta-1,  subunit beta-2, subunit epsilon-Y2 
  990.96 15 116 1.20E-10  YFDSFGDLSSASAIMGNAK subunit beta-1, 
Pyruvate kinase isozymes M1/M2 134 793.89 12 95 3.70E-08  DAVLNAWAEDVDLR M1/M2 
  588.97 -28 39 0.023  KGVNLPGAAVDLPAVSEK M1/M2 
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Table 4.3 (cont.) Mascot results from LC-MS/MS analysis of on-bead trypsin digested biotinyl (R)-lacosamide analogue A enriched mouse brain 
samples after SCX separation. Significant peptide score was 29 (p<0.05). False discovery rate was approximately 2.5% 
 
Protein identification Protein score 
Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
Guanine nucleotide-binding protein G(o) subunit alpha 
1 
121 529.34 52 67 1.00E-05  LLLLGAGESGK G(o), G(olf), G(k), G(t), G(i), G(s) subunit alpha 1 
  838.44 36 54 0.00022  IGAGDYQPTEQDILR G(o) subunit alpha 1 
ADP/ATP translocase 1 138 451.75 25 38 0.009  GAWSNVLR 1, 2 
  585.29 11 35 0.016  EQGFLSFWR 1 
  723.88 17 65 3.90E-05  YFPTQALNFAFK 1,2,4 
Enolase gamma 128 902.97 14 91 5.00E-08 AAVPSGASTGIYEALELR alpha, beta, gamma 
  580.79 38 37 0.018 IEEELGDEAR gamma 
Enolase alpha 127 902.97 14 91 5.00E-08 AAVPSGASTGIYEALELR alpha, beta, gamma 
  452.70 -28 36 0.0084 IEEELGSK alpha 
Clathrin heavy chain 1 128 555.84 10 48 0.0011  LLLPWLEAR 1 
  652.84 21 39 0.0065  NNLAGAEELFAR 1 
  904.03 -38 41 0.0026 ADDPSSYMEVVQAANASGNWEELVK 1 
Sodium/potassium-transporting ATPase subunit beta-1 99 670.87 20 31 0.055  SYEAYVLNIIR subunit beta-1 
  745.44 11 68 8.20E-06  VAPPGLTQIPQIQK subunit beta-1 
Fructose-bisphosphate aldolase A 108 666.85 12 68 9.70E-06  GILAADESTGSIAK aldolase A 
  671.89 53 40 0.0042  ADDGRPFPQVIK aldolase A 
2',3'-cyclic-nucleotide 3'-phosphodiesterase 106 523.94 -21 62 5.20E-05 KAGQVFLEELGNHK - 
  628.85 57 44 0.002 GGSQGEAVGELPR - 
Histone 4 107 495.28 -14 53 0.0004  VFLENVIR 4 
  590.78 -35 54 0.00023  ISGLIYEETR 4 
Triosephosphate isomerase 107 624.32 40 60 1.20E-05 SNVNDGVAQSTR - 
  1010.53 12 47 0.002 ELASQPDVDGFLVGGASLKPEFVDIINAK - 
ATP synthase subunit beta 129 801.44 42 32 0.060  VALVYGQMNEPPGAR subunit beta 
  994.54 27 48 0.00059  AIAELGIYPAVDPLDSTSR subunit beta 
  675.01 15 49 0.0013  FLSQPFQVAEVFTGHMGK subunit beta 
Syntaxin-binding protein 1 127 662.83 18 30 0.032  RMNTGEKTTMR 1 
  943.56 49 45 0.0022  EPLPSLEAVYLITPSEK 1 
  661.96 -37 52 0.00015  MNTGEKTTMRDLSQMLK 1 
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Table 4.3 (cont.) Mascot results from LC-MS/MS analysis of on-bead trypsin digested biotinyl (R)-lacosamide analogue A enriched mouse brain 
samples after SCX separation. Significant peptide score was 29 (p<0.05). False discovery rate was approximately 2.5% 
 
Protein identification Protein score 
Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
Heat shock protein HSP 90-beta 112 510.07 -33 32 0.054  NNIKLYVR HSP 90-beta, HSP 90-alpha 
  618.84 35 38 0.0092  RAPFDLFENK HSP 90-beta 
  982.85 21 42 0.0001 TLTLVDTGIGMTKADLINNLGTIAKSGTK HSP 90-beta 
Elongation factor 1-alpha 1 62 513.30 -11 32 0.076  IGGIGTVPVGR 1-alpha 1, 1-alpha 2 
  664.36 40 30 0.095  QTVAVGVIKAVDK 1-alpha 1 
Creatine kinase B-type 196 652.39 37 44 0.0024  VLTPELYAELR B-type 
  801.94 33 85 1.90E-07  LAVEALSSLDGDLSGR B-type 
  439.77 43 43 0.0029  FSEVLKR B-type 
  840.07 19 24 0.13  TDLNPDNLQGGDDLDPNYVLSSR B-type 
14-3-3 protein zeta/delta 189 454.23 -53 37 0.012  NLLSVAYK theta, beta/alpha, gamma, eta, epsilon, sigma, zeta/delta 
  595.34 22 36 0.038  DSTLIMQLLR theta, beta/alpha, gamma, eta, epsilon, sigma, zeta/delta 
  665.86 21 33 0.057  FLIPNASQPESK zeta/delta 
  1020.96 -29 83 1.80E-07  GIVDQSQQAYQEAFEISK zeta/delta 
Malate dehydrogenase, mitochondrial precursor 109 727.86 18 36 0.035  AGAGSATLSMAYAGAR mitochondrial precursor 
  780.93 32 73 6.40E-06  VDFPQDQLATLTGR mitochondrial precursor 
Dihydropyrimidinase-related protein 2 232 454.73 -30 34 0.017  VFNLYPR 2 
  570.82 -12 34 0.020  KPFPDFVYK 2 
  863.42 21 53 0.0002  MDENQFVAVTSTNAAK 2 
  958.49 14 33 0.022  ISVGSDADLVIWDPDSVK 2 
  915.15 25 42 0.0032  MDENQFVAVTSTNAAKVFNLYPRK 2 
 
 
982.51 19 36 0.040 
 
QQAPPVRNLHQSGFSLSGAQIDDNIP
R 
2 
14-3-3 protein gamma 78 595.34 22 36 0.038  DSTLIMQLLR theta, beta/alpha, gamma, eta, epsilon, sigma, zeta/delta 
 
 
1101.19 -12 42 0.0011 
 
TAFDDAIAELDTLNEDSYKDSTLIMQL
LR 
gamma 
 
“ppm” refers to the difference between observed precursor ion mass and expected for the identified peptide. 
“Expectation value”  refers to the number of times that expect to obtain this score or better by chance. 
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4.5. Discussion 
 
 The ligand-based affinity purification strategy was shown to be efficient to 
enrich target proteins from mouse brain lysate. The experiments were carried out in triplicate 
for improved confidence of the data for identification. The reported peptides were observed 
in all three experiments and had an ion score above significant score at 95% confidence. A 
total of 28 candidate target proteins of lacosamide were identified and have been presented 
in this chapter. Only keratin was observed from the negative control experiment (a common 
contaminant for MS experiment). It is possible to miss identification of low concentration 
proteins during silver staining as there is not enough protein for band visualization. The on-
bead digestion protocol coupled with SCX separation of peptides prior to LC-MS/MS 
increased the capability of detecting candidate target proteins (Table 4.4).  Some identified 
proteins are housekeeping proteins, which show high abundance in cells, for example actin 
and glyceraldehyde-3-phosphate dehydrogenase107. Because of their abundance in cell 
lysates, their observation here may be attributable to non-selective binding with the 
streptavidin (despite their non-detection in controls).  However, dihydropyrimidinase-related 
protein  presents in low abundance in brain cell 108 but it was shown as a high abundance 
protein after enriching. The 14-3-3 protein zeta/delta, sodium/potassium-transporting 
ATPase subunit alpha 3 and creatine kinase B-type were also interesting in terms of their 
large number of confidently identified peptides (4 peptides). No lacosamide analogue-
modified peptides were detected in any of these experiments as the modified peptides 
remain bound to the enrichment column; only non-modified peptides resulting from tryptic 
digestion of the bound proteins underwent analysis. In order to increase the confidence in 
identification of lacosamide analogue bound proteins, a strategy was developed specifically 
to identify modified peptides from these samples. This work is presented in chapter 7.  
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Table 4.4 Summary of protein identification from LC-MS/MS analysis of in-gel 
digestion, on-bead digestion before and after SCX separation. 
 
No of peptides Protein identifications 
In-gel 
digestion 
On-bead 
digestion 
(before SCX) 
On-bead 
digestion 
(after SCX) 
Actin cytoplasmic 1, gamma-enteric smooth muscle, alpha 
cardiac muscle 1, aortic smooth muscle, alpha skeletal muscle 
1 - - 
ADP/ATP translocase 1 3 2 3 
14-3-3 protein zeta/delta 3 3 4 
Glyceraldehyde-3-phosphate dehydrogenase 2 2 3 
Malate dehydrogenase mitochondrial precursor 2 2 2 
Elongation factor 1 alpha 1  3 2 2 
Enolase alpha 3 3 2 
ATP synthase subunit alpha  4 2 4 
Dihydropyrimidinase-related protein  2 2 3 6 
Histone 4 2 2 2 
Sodium/potassium-transporting ATPase subunit alpha 3 - 7 7 
14-3-3 protein gamma - 3 2 
ATP synthase subunit beta - 2 3 
Creatine kinase B-type - 1 4 
Fructose-bisphosphate aldolase A - 3 2 
Syntaxin-binding protein 1 - 1 3 
Vesicle-fusing ATPase - 1 3 
Enolase gamma - 2 2 
Guanine nucleotide-binding protein G(o) subunit alpha - 2 2 
2',3'-cyclic-nucleotide 3'-phosphodiesterase - 2 2 
Sodium/potassium-transporting ATPase subunit alpha 1 - - 5 
Fructose-bisphosphate aldolase C - - 2 
Hemoglobin subunit beta-1 - - 2 
Clathrin heavy chain 1 - - 3 
Sodium/potassium-transporting ATPase subunit beta-1 - - 2 
Triosephosphate isomerase - - 2 
Heat shock protein HSP 90-beta - - 3 
Pyruvate kinase isozymes M1/M2 - - 2 
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CHAPTER 5 
Results III 
Comparison of protein binding between (R)- and 
(S)- lacosamide analogue A 
 
5.1. Introduction 
 
Our collaborators from the Eshelman School of Pharmacy, University of North 
Carolina found that (R)-lacosamide analogue A exhibited anticonvulsant activity in mice 
(ED50 = 45 mg/kg) while the corresponding (S)-lacosamide analogue A did not  (ED50 = >300 
mg/kg). Unlike the work described in the previous chapter which used a biotin tag, these 
studies use a fluorescent rhodamine probe to select target proteins.  Soluble and membrane 
fractions from mouse brain lysates were treated with (R)- and (S)- lacosamide analogue A 
and the lysate mixture reacted with an appropriate rhodamine probe. The reaction samples 
were separated by SDS-PAGE and then analysed for labelled proteins by in-gel 
fluorescence using a typhoon scanning imager. Bands observed preferentially in samples 
treated with the (R)- rather than (S)- lacosamide analogue A were shipped without buffer in 
ambient temperature to Manchester and further analysed using MS.  
 
5.2. Identification of candidate target proteins from mouse brain soluble lysate 
 
 Analysis of the rhodaminyl (R)- and (S)- lacosamide analogue A modified soluble 
lysate gel patterns showed that some proteins were more susceptible to modification by the 
(R)- enantiomer than (S)- form of lacosamide analogue A. In particular two proteins of 
molecular mass ~62 and 25 kDa showed preference of (R)- over (S)- lacosamide analogue 
A (Figure 5.1). To identify the protein in these bands, additional studies were conducted to 
verify the selective modification of proteins by (R)-lacosamide analogue A. First, the (R)-
lacosamide analogue A lysate adduction was repeated. The modified lysate was then treated 
with biotinyl probe. The biotinylated proteins were captured with streptavidin beads, the 
beads were stringently washed to remove background proteins adsorbed on the resin, and 
then the protein adducts released with SDS treatment. SDS-PAGE electrophoresis showed 
bands at ~62 kDa upon Coomassie blue staining and ~25 kDa upon silver staining (Figure 
5.2). These studies were undertaken by Ki Duk Park in the laboratory of Prof. Harold Kohn at 
the University of North Carolina.  These ~62 and 25 kDa gel samples were sent to 
Manchester for protein identification by in-gel digestion. 
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Figure 5.1 The rhodaminyl (R)- and (S)-lacosamide analogue A labelled mouse brain 
soluble lysate proteins were detected by in-gel fluorescence. All images are shown in 
gray scale. The 62 kDa band in 8% gel shows preference of (R)-enantiomer (left). The 25 
kDa band in 10% gel shows preference of (R)-enantiomer (right). Figure provided by Ki Duk 
Park. 
   
 
Figure 5.2 Coomassie blue stained gel of mouse brain soluble lysate after incubation 
with biotinyl (R)-lacosamide analogue A and no drug (left), and enrichment using streptavidin 
beads. Silver stained gel of mouse brain lysate after enriched by biotinyl (R)-lacosamide 
analogue A and no drug right). Figure provided by Ki Duk Park. 
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The 62 and 25 kDa bands were excised, digested with trypsin and analysed by LC-
MS/MS. Analysis of the tryptic fragments indicated the presence of several proteins whose 
molecular weights were consistent with their electrophoretic mobility (Table 5.1). Many 
proteins were identified from the 62 and 25 kDa gel bands. From the 25 kDa band in the (R)-
lacosamide analogue A reaction, only members of the 14-3-3 protein family could be 
identified. Isoform specific peptides confirmed the presence of five different isoforms and 
they were not observed in 25 kDa band in the no drug control reaction (Figure 5.3). It meant 
that they are likely to be targets of (R)-lacosamide. In this experiment, the false positive rate 
was estimated at 3.5% approximately, which was acceptable because it was less than 5%, 
the maximum acceptable rate for general proteomics studies. Further studies to identify the 
sites of modification on these interesting candidate target proteins were performed and have 
been described in chapter 7.  
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Table 5.1 LC-MS/MS Mascot results In-gel trypsin digestions of mouse brain lysate after enriched by biotinyl (R)-lacosamide analogue A and 
controls on 25 and 62 kDa bands. Significant peptide score was approximately 28 (p<0.05). False discovery rate was approximately 2.32%. 
 
 
 
 
 
 
 
 
 
 
Sample Protein identification 
Protein score Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
25 kDa band from 
R lane 14-3-3 protein gamma 693 452.25 -21 38 0.012 VISSIEQK gamma, theta. eta, beta-alpha 
   454.27 25 53 0.00024 NLLSVAYK theta, beta, zeta-delta, gamma, eta,epsilon, sigma, beta-alpha 
   508.23 45 73 3.50E-06 YDDMAAAMK beta-alpha, gamma 
   540.79 28 62 3.30E-05 YLAEVATGEK gamma 
   595.34 23 40 0.0046 DSTLIMQLLR theta, beta-alpha, zeta-delta, gamma, eta, epsilon, sigma 
   822.42 36 112 2.70E-10 NVTELNEPLSNEER gamma 
   1066.01 29 105 1.20E-09 TAFDDAIAELDTLNEDSYK gamma 
   1097.46 23 103 1.70E-09 DNLTLWTSDQQDDDGGEGNN gamma 
   1101.24 35 107 1.00E-09 TAFDDAIAELDTLNEDSYKDSTLIMQLLR gamma 
 14-3-3 protein zeta-delta 526 454.27 25 53 0.00024 NLLSVAYK 
theta, beta, zeta-delta, gamma, eta,epsilon, 
sigma, beta-alpha 
   576.30 41 39 0.0058 YLAEVAAGDDK zeta-delta 
   595.34 23 40 0.0046 DSTLIMQLLR theta, beta-alpha, zeta-delta, gamma, eta, epsilon, sigma 
   640.35 42 70 4.80E-06 YLAEVAAGDDKK zeta-delta 
   774.90 46 111 3.70E-10 SVTEQGAELSNEER zeta-delta 
   1021.01 22 103 1.80E-09 GIVDQSQQAYQEAFEISK zeta-delta 
   1205.07 55 110 3.40E-10 DNLTLWTSDTQGDEAEAGEGGEN zeta-delta 
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Table 5.1(cont.) LC-MS/MS Mascot results In-gel trypsin digestions of mouse brain lysate after enriched by biotinyl (R)-lacosamide analogue A and 
controls on 25 and 62 kDa bands. Significant peptide score was approximately 33 (p<0.05). False discovery rate was approximately 3.5%.  
 
 
 
 
 
Sample Protein identification 
Protein 
score 
Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
25 kDa band from 
R lane 
14-3-3 protein beta-
alpha 
510 452.25 -21 38 0.012  VISSIEQK gamma, theta. eta, beta-alpha 
   454.27 25 53 0.00024  NLLSVAYK theta, beta, zeta-delta, gamma, eta,epsilon, sigma, beta-alpha 
   508.23 45 73 3.50E-06  YDDMAAAMK beta-alpha, gamma 
   595.34 23 40 0.0046  DSTLIMQLLR theta, beta-alpha, zeta-delta, gamma, eta, epsilon, sigma 
   598.81 40 80 4.30E-07  YLSEVASGENK beta-alpha 
   799.89 31 82 3.30E-07  AVTEQGHELSNEER beta-alpha 
   1080.03 22 75 1.10E-06  QTTVSNSQQAYQEAFEISK beta-alpha 
   1176.02 42 69 4.50E-06  DNLTLWTSENQGDEGDAGEGEN beta-alpha 
 14-3-3 protein theta 319 452.25 -21 38 0.012  VISSIEQK gamma, theta. eta, beta-alpha 
   454.27 25 53 0.00024  NLLSVAYK theta, beta, zeta-delta, gamma, eta,epsilon, sigma, beta-alpha 
   595.34 23 40 0.0046  DSTLIMQLLR theta, beta-alpha, zeta-delta, gamma, eta, epsilon, sigma 
   766.91 58 107 1.10E-09  AVTEQGAELSNEER theta 
   1015.01 38 81 3.60E-07  QTIENSQGAYQEAFDISK theta 
 14-3-3 protein eta 231 452.25 -21 38 0.012  VISSIEQK gamma, theta. eta, beta-alpha 
   454.27 25 53 0.00024  NLLSVAYK theta, beta, zeta-delta, gamma, eta,epsilon, sigma, beta-alpha 
   595.34 23 40 0.0046  DSTLIMQLLR theta, beta-alpha, zeta-delta, gamma, eta, epsilon, sigma 
   793.91 39 100 5.20E-09  AVTELNEPLSNEDR eta 
 Keratin type II cytoskeletal 1b 
123 436.89 36 36 0.012  NKYEDEINKR type II cytoskeletal 8, type II cytoskeletal 79, type II cytoskeletal 1b, type II cytoskeletal 5 
 
  
738.42 42 87 8.90E-08  FLEQQNQVLQTK 
type II cytoskeletal 71, type II cytoskeletal 73, 
type II cytoskeletal 1b, type II cytoskeletal 74, 
type II cytoskeletal 1 
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Table 5.1 (cont.) LC-MS/MS Mascot results in-gel trypsin digestions of mouse brain lysate after enriched by biotinyl (R)-lacosamide analogue A and 
controls on 25 and 62 kDa bands. Significant peptide score was approximately 33 (p<0.05). False discovery rate was approximately 3.5%.  
 
 
 
 
 
 
Sample Protein identification 
Protein 
score 
Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
25 kDa band from 
No drug lane 
Keratin type II 
cytoskeletal 1b 
123 576.80 47 38 0.0082  NKYEDEINK type II cytoskeletal 8, type II cytoskeletal 79, type II cytoskeletal 1b, type II cytoskeletal 5 
 
  
738.43 53 85 9.40E-08  FLEQQNQVLQTK 
type II cytoskeletal 71, type II cytoskeletal 73, 
type II cytoskeletal 1b, type II cytoskeletal 74, 
type II cytoskeletal 1 
62 kDa band from 
R lane 
Dihydropyrimidinase-
related protein 2 
1329 439.74 49 39 0.0074  MSVIWDK 2,3 
   454.77 51 44 0.0021  VFNLYPR 2 
   508.30 41 77 1.40E-06  SAAEVIAQAR 2 
   542.84 47 78 2.80E-07  GSPLVVISQGK 1,2 
   380.88 34 44 0.0019  KPFPDFVYK 2 
   623.84 42 83 2.20E-07  GIQEEMEALVK 2 
   647.87 41 67 9.90E-06  MVIPGGIDVHTR 2,3 
   662.40 33 47 0.00068  QIGENLIVPGGVK 1,2 
   841.96 34 91 3.70E-08  IVLEDGTLHVTEGSGR 2 
   871.43 36 101 3.40E-09  MDENQFVAVTSTNAAK + Oxidation (M) 1,2,3 
   956.03 25 131 3.10E-12  FQLTDSQIYEVLSVIR 2 
   958.50 23 75 1.30E-06  ISVGSDADLVIWDPDSVK 2 
   1075.98 24 118 7.30E-11  FQMPDQGMTSADDFFQGTK 2 
   1085.06 28 102 2.90E-09  NLHQSGFSLSGAQIDDNIPR 2 
   728.08 44 50 0.00035  DRFQLTDSQIYEVLSVIR 2 
   1183.11 56 117 7.00E-11  IVNDDQSFYADIYMEDGLIK + Oxidation (M) 2,3 
 
  
967.57 66 65 9.90E-06 
 
ILDLGITGPEGHVLSRPEEVEAEAVN
R 
2 
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Table 5.1 (cont.) LC-MS/MS Mascot results In-gel trypsin digestions of mouse brain lysate after enriched by biotinyl (R)-lacosamide analogue A and 
controls on 25 and 62 kDa bands. Significant peptide score was approximately 33 (p<0.05). False discovery rate was approximately 3.5%.  
 
 
 
 
 
 
 
Sample Protein identification Protein score 
Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
62 kDa band from 
R lane 
Dihydropyrimidinase-
related protein 1 
492 500.81 44 88 1.00E-07  SAADIIALAR 1 
   654.37 41 52 0.0003  IVFEDGNISVSK 1 
   662.40 33 47 0.00068  QIGENLIVPGGVK 1,2 
   871.43 36 101 3.40E-09  MDENQFVAVTSTNAAK + Oxidation (M) 1,2,3 
   1100.09 62 95 1.20E-08 DLYQMSDSQLYEAFTFLK 1 
   1166.14 59 109 4.70E-10  IINDDQSFYADVYLEDGLIK 1 
 Syntaxin-binding protein 1 333 612.83 37 78 7.10E-07  ISEQTYQLSR 1 
   634.85 38 74 1.90E-06  HIAEVSQEVTR 1 
   636.34 47 81 4.90E-07  SSASFSTTAVSAR 1 
   796.89 48 100 4.60E-09  VEQDLAMGTDAEGEK 1 
 Phosphoglucomutase 1 351 545.81 39 95 1.80E-08  LSGTGSAGATIR 1 
   601.33 42 61 4.20E-05  QEATLVVGGDGR 1 
   758.85 41 88 7.90E-08  YDYEEVEAEGANK 1 
   809.96 57 40 0.0048  TQAYPDQKPGTSGLR 1 
   982.58 22 67 6.50E-06  INQDPQVMLAPLISIALK 1 
 Serum albumin 279 575.34 61 47 0.0011  LVQEVTDFAK - 
   720.42 43 58 6.00E-05  APQVSTPTLVEAAR - 
   740.43 49 80 3.30E-07  LGEYGFQNAILVR - 
   805.42 36 94 1.90E-08  DVFLGTFLYEYSR - 
 Transketolase 195 435.25 -24 52 0.00023  LAVSQVPR - 
   632.86 58 39 0.0061  ISSDLDGHPVPK - 
   1005.04 44 104 1.50E-09  NMAEQIIQEIYSQVQSK - 
                                      Results III Chapter 5 
92 
Table 5.1 (cont.) LC-MS/MS Mascot results In-gel trypsin digestions of mouse brain lysate after enriched by biotinyl (R)-lacosamide analogue A and 
controls on 25 and 62 kDa bands.  Significant peptide score was approximately 33 (p<0.05). False discovery rate was approximately 3.5%.  
 
  
“ppm” refers to the difference between observed precursor ion mass and expected for the identified peptide. 
“Expectation value”  refers to the number of times that expect to obtain this score or better by chance. 
“ – “ means that no isoform specified. 
 
 
 
 
 
 
Sample Protein identification Protein score 
Observed 
m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
62 kDa band from 
R lane 
Glutamate decarboxylase 1 163 955.51 37 42 0.0028  TETDFSNLFAQDLLPAK 1 
   1246.15 28 121 2.60E-11  MVISNPAATQSDIDFLIEEIER 1 
 Stress-induced-phosphoprotein 1 
199 526.29 33 46 0.001  SLLSDPTYR 1 
   728.40 50 38 0.0081  LDPQNHVLYSNR 1 
   744.93 48 70 5.00E-06  LAYINPDLALEEK 1 
   629.69  45 0.0014  TYEEGLKHEANNLQLK 1 
 T-complex protein 1 subunit gamma 
119 487.79 54 40 0.0059  EILSEVER 1 subunit gamma 
   1066.15 61 74 1.40E-06  MLLDPMGGIVMTNDGNAILR 1 subunit gamma 
 Dihydropyrimidinase-related protein 4 
101 481.24 12 75 2.00E-06  GAADMVAQAK 4 
   901.95 11 26 0.22  DNFTLIPEGVNGIEER 4 
 Keratin type II cytoskeletal 1 118 697.40 52 46 0.0012  TNAENEFVTIKK type II cytoskeletal 1 
   738.42 43 72 3.20E-06  FLEQQNQVLQTK type II cytoskeletal 1, 71, 73, 1b, 74 
62 kDa band from 
No drug lane 
Keratin type II cytoskeletal 1 204 633.35 55 52 0.00029  TNAENEFVTIK type II cytoskeletal 1 
   697.41 63 69 5.20E-06  TNAENEFVTIKK type II cytoskeletal 1 
   738.43 54 83 2.10E-07  FLEQQNQVLQTK type II cytoskeletal 1, 71, 73, 1b, 74 
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Figure 5.3 CID product ion spectra (A) Doubly protonated peptide specific to gamma isoform at m/z 822.42. (B) Doubly protonated peptide specific to 
zeta/delta isoform at m/z 774.90. (C) Doubly protonated peptide specific to beta/alpha isoform at m/z 799.89. (D) Doubly protonated peptide specific to theta 
isoform at m/z 766.91. (E) Doubly protonated peptide specific to eta isoform at m/z 793.91. 
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From the 62 kDa band in the (R)-lacosamide analogue A reaction, dihydropyrimidinase-
related protein 2 (CRMP2) was detected (17 peptides including 11 peptides unique to 
CRMP2 and 6 peptides common to other CRMP proteins, 45% sequence coverage), 
followed by CRMP1 (6 peptides including 4 peptides unique to CRMP1 and 2 peptides 
common to other CRMP proteins, 17% coverage)109. According to this generalisation, 
CRMP2 was a likely major constituent followed by CRMP1 in the ~62 kDa band. To estimate 
amount of CRMP2 and CRMP1 (the first and second most abundant proteins in the 62 kDa 
band), emPAI (exponentially modified protein abundance index) was used. It was developed 
by Ishihama et al.110 to measure the protein composition in sample solutions. When the total 
protein amount in the sample is available, emPAI can be converted to the absolute amount 
of each protein in the sample. emPAI is derived from PAI, which is defined as the number of 
the observed peptides divided by the number of the observable peptides per protein. It was 
recently found that log (PAI) had linear relationship to the protein amounts, and that emPAI, 
10(PAI)-1, was proportional to whole protein amounts digested by trypsin. The accuracy of this 
method was similar or better than determination of abundance by protein staining110. Since 
the emPAI index does not require further experimentation in protein identification 
experiments, it was decided to use this to estimate the relative abundances of CRMP2 and 
CRMP1. According to the data, emPAI values of CRMP2 and CRMP1 were 2.28 and 0.51, 
meaning that the amount of CRMP2 in the 62 kDa band was 4.45 fold higher than CRMP1. 
To validate the preference of CRMP2 binding to (R)-lacosamide analogue A over 
(S)-lacosamide analogue A, a quantitative comparison of the proteins in the sample from the 
band excised at 62 kDa was performed using differential stable isotope labelling (iTRAQ)99. 
The tryptic digests from the (R)-lacosamide analogue A, (S)-lacosamide analogue A, the no 
drug control reaction, and iTRAQ buffer alone were each separately treated with distinct 
iTRAQ isotope labels, the samples were combined and then analysed by LC-MS/MS. 
Peptide intensities were normalised to the tubulin peptide, based on the assumption that 
apparent binding to tubulin represents non-selective retention of tubulin on the streptavidin 
beads and  no stereochemical preference. There was no difference in observed iTRAQ ratio 
between fragments unique to CRMP2 and those common to other CRMP proteins (Table 
5.2).The peptides specific to CRMP2, showed on average, a 1.35:1 increase in the relative 
amounts of each tryptic fragment from the (R)-lacosamide analogue A treated sample 
compared with (S)-lacosamide analogue A. All of the CRMP2 peptides (including peptides 
associated with other CRMP isoforms) showed on average, a 1.39:1 increase in the (R)- 
lacosamide analogue A reaction compared with the (S)-lacosamide analogue A reaction. 
Analysis of all CRMP1 peptides also showed a 1.46:1 preference between the (R)- 
lacosamide analogue A compared with the (S)-lacosamide analogue A. A CID mass 
spectrum of an iTRAQ labelled on CRMP2 peptide is shown in figure 5.4. This differential 
amount in tryptic fragment abundances was in broad agreement with the observed ratio for 
the fluorescence intensities of the 62 kDa band in the (R)-lacosamide analogue A reaction 
versus the (S)- lacosamide analogue A experiment (Fig. 5.1).  
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Table 5.2 Quantification of the (R)- and (S)-biotinyl lacosamide analogue A of the 62kDa using iTRAQ. 
 
Identified 
Protein Peptide Protein Observed m/z 
Ion 
score 
Expectation 
value R/S 
Average± 
S.D. 
SAAEVIAQAR CRMP2 580.80 54 0.00022 1.14  
MVIPGGIDVHTR CRMP2 720.41 53 0.00027 1.60  
IVLEDGTLHVTEGSGR CRMP2 914.43 33 0.023 1.46  
ISVGSDADLVIWDPDSVK CRMP2 1031.01 82 2.80E-07 1.27  
FQMPDQGMTSADDFFQGTK CRMP2 1148.49 59 5.40E-05 1.35  
AVVTGKMDENQFVAVTSTNAAK CRMP2 857.74 47 0.00098 1.20  
ILDLGITGPEGHVLSRPEEVEAEAVNR CRMP2 1015.87 77 9.30E-07 1.43 1.35± 0.16 
MSVIWDK CRMP2,3 512.24 40 0.0058 1.40  
IVNDDQSFYADIYMEDGLIK CRMP2,3 1247.58 62 3.00E-05 1.37  
QIGENLIVPGGVK CRMP1,2 734.91 72 3.50E-06 1.88  
CRMP2 
MDENQFVAVTSTNAAK CRMP1,2,3 935.93 35 0.018 1.21 1.39±0.21 
SAADIIALAR CRMP1 573.31 46 0.0012 1.33  
MTVVWDK CRMP1 512.25 40 0.0062 1.43      
QIGENLIVPGGVK CRMP1,2 734.91 72 3.50E-06 1.88  
CRMP1 
MDENQFVAVTSTNAAK CRMP1,2,3 935.93 35 0.018 1.21 1.46±0.29 
Tubulin  AVFVDLEPTVIDEVR TBA 923.98 72 3.00E-06 1.00 - 
 
 
“Expectation value” refers to the number of times that expect to obtain this score or better by chance. 
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Figure 5.4 CID product ion spectrum (A) Doubly protonated iTRAQ labelled on CRMP2 peptide (ILDLGITGPEGHVLSRPEEVEAEAVNR) at m/z 1015.87. 
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Finally, collaborators at the UNC Eshelman School of Pharmacy generated CRMP2 
as a glutathione-S-transferase (GST) fusion protein (increasing its size by 25 kDa) in order to 
perform quantitative in vitro binding assays. The purified recombinant GST-CRMP2 protein 
(10 μg) was incubated with the lysate (50 μL at 2 mg/mL), and the adduction reaction was 
repeated with (R)-lacosamide analogue A, (S)-lacosamide analogue A, and no drug. The 
reaction products were treated with the rhodamine probe and then separated by SDS-PAGE. 
The electrophoretic mobility of the GST-CRMP2 (82 kDa) placed it in a region that was 
relatively free of other binding proteins in the soluble fraction (Figure 5.5). An increase in 
fluorescent intensity of approximately 1.5-fold was observed for the (R)-lacosamide analogue 
A modified GST-CRMP2 protein (based on electrophoretic mobility) compared with the 
corresponding (S)-lacosamide analogue A modified recombinant protein. By comparison, the 
(R)-lacosamide analogue A modified endogenous 62 kDa band was approximately 1.8-fold 
more intense than the corresponding (S)-lacosamide analogue A modified band. Western 
blot analysis of the 82 kDa band was in agreement with the presence of CRMP2 and GST 
using anti-CRMP2 and anti-GST antibodies. Collectively, these studies show that CRMP2 is 
preferentially modified in the lysate by (R)-lacosamide analogue A and leads to higher 
CRMP2 adduction levels than the corresponding (S)- lacosamide analogue A derivative. 
 
Figure 5.5 In-gel fluorescence scanning after treated with the rhodaminyl (R)- and (S)-
lacosamide analogue A of externally added GST-CRMP2 and endogenous CRMP2 in 
mixture of mouse lysate and overexpressed GST-CRMP2.  
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5.3. Identification of candidate target proteins from mouse brain membrane lysate             
 
Mouse brain membrane lysates were treated with (R)- and (S)- lacosamide analogue 
A and the lysate mixture reacted with an appropriate rhodamine probe as above. The 
reaction samples were separated by electrophoresis and then fluorescent proteins were 
detected using a typhoon scanning imager. Analysis of the rhodaminyl (R)- and (S)- 
lacosamide analogue A modified membrane lysate gel patterns showed that a band 
migrating at ~83 KDa were modified preferentially by (R)- than (S)- lacosamide analogue A 
(Figure 5.6). 
. 
 
Figure 5.6 The rhodaminyl (R)- and (S)-lacosamide analogue A labeled mouse brain 
membrane lysate proteins were detected by in-gel fluorescence. All images are shown 
in gray scale. The 83 kDa band shows preference of (R)-enantiomer. Figure provided by Ki 
Duk Park. 
 
 
To identify the protein(s) in these bands, the (R)-lacosamide analogue A lysate adduction 
was repeated and the modified lysate was treated with the biotinyl probe. The biotinylated 
proteins were captured with streptavidin beads, the beads stringently washed to remove 
background proteins adsorbed on the resin, and then the protein adducts released with SDS 
treatment. Silver staining of the SDS-polyacrylamide gel showed bands at ~83 kDa (Figure 
5.7). 
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Figure 5.7 Silver stained gel of mouse brain membrane lysate after enrichment by 
biotinyl (R)-lacosamide analogue A and no drug. Figure provided by Ki Duk Park. 
      
The 83 kDa band was excised, digested with trypsin, and analysed by LC-MS/MS. Analysis 
of the tryptic peptides indicated the presence of several proteins whose molecular weights 
were consistent with their electrophoretic mobility (Table 5.3). From the 83 kDa band in the 
(R)-lacosamide analogue A reaction, only sodium/potassium-transporting ATPase family 
could be identified. The three isoforms were indicated from specific peptides (Figure 5.8). 
Proteins of the sodium/potassium-transporting ATPase family were not observed in 83 kDa 
band in the no drug control reaction. In this experiment, the false positive rate was estimated 
at 3.0% approximately, which was acceptable because it was less than 5%, the maximum 
acceptable rate for general proteomics studies. This protein family also shows high potential 
to be real targets of lacosamide.  
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Table 5.3 LC-MS/MS Mascot results from LC-MS/MS analysis following CID of In-gel trypsin digestions of mouse brain lysate after enriched by 
biotinyl (R)-lacosamide analogue A and controls on 83 kDa band. Significant peptide score was approximately 29 (p<0.05). False discovery rate was 
approximately 3.0%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“ppm” refers to the difference between observed precursor ion mass and expected for the identified peptide. 
“Expectation value” refers to the number of times that expect to obtain this score or better by chance. 
 
Sample Protein identification Observed m/z ppm 
Ion 
score 
Expectation 
value Sequence Isoforms 
83 kDa band from R lane 
Sodium/potassium-transporting 
ATPase subunit alpha-3  
 
579.86 35 69 6.50E-06  IATLASGLEVGK subunit  alpha-3 
  610.34 45 31 0.042 VAEIPFNSTNK subunit alpha-2, 3, 4 
  618.87 34 54 0.0002 LNIPVSQVNPR subunit  alpha-2, 3 
  634.89 51 43 0.0023 NMVPQQALVIR subunit  alpha-1, 2, 3, 4 
  638.34 35 74 1.80E-06 DVAGDASESALLK subunit  alpha-3 
  691.40 39 39 0.0061 VIMVTGDHPITAK subunit  alpha-1, 2, 3 
  906.49 21 99 5.70E-09 QGAIVAVTGDGVNDSPALK subunit  alpha-1, 2, 3, 4 
  915.48 23 100 4.00E-09 GVGIISEGNETVEDIAAR subunit  alpha-1, 2, 3 
  647.38 49 68 7.10E-06 QGAIVAVTGDGVNDSPALKK subunit  alpha-1, 2, 3, 4 
 Sodium/potassium-transporting ATPase subunit alpha-2 610.34 45 31 0.042 VAEIPFNSTNK subunit alpha-2, 3, 4 
  618.87 34 54 0.0002 LNIPVSQVNPR subunit  alpha-2, 3 
  634.89 51 43 0.0023 NMVPQQALVIR subunit  alpha-1, 2, 3, 4 
  639.34 50 63 2.80E-05 DTAGDASESALLK subunit  alpha-2 
  691.40 39 39 0.0061 VIMVTGDHPITAK subunit  alpha-1, 2, 3 
  906.49 21 99 5.70E-09 QGAIVAVTGDGVNDSPALK subunit  alpha-1, 2, 3, 4 
  915.48 23 100 4.00E-09 GVGIISEGNETVEDIAAR subunit  alpha-1, 2, 3 
  647.38 49 68 7.10E-06 QGAIVAVTGDGVNDSPALKK subunit  alpha-1, 2, 3, 4 
 Sodium/potassium-transporting ATPase subunit  alpha-1 632.39 52 38 0.008 LNIPVNQVNPR subunit  alpha-1 
  634.89 51 43 0.0023 NMVPQQALVIR subunit  alpha-1, 2, 3, 4 
  691.40 39 39 0.0061 VIMVTGDHPITAK subunit  alpha-1, 2, 3 
  760.37 30 59 6.60E-05 SPDFTNENPLETR subunit  alpha-1 
  906.49 21 99 5.70E-09 QGAIVAVTGDGVNDSPALK subunit  alpha-1, 2, 3, 4 
  915.48 23 100 4.00E-09 GVGIISEGNETVEDIAAR subunit  alpha-1, 2, 3 
  647.38 49 68 7.10E-06 QGAIVAVTGDGVNDSPALKK subunit  alpha-1, 2, 3, 4 
 Keratin,  type II cytoskeletal 71, 72, 73, 1b, 1, 74 738.41 28 63 2.40E-05 FLEQQNQVLQTK 
type II cytoskeletal 71, 72, 
73, 1b, 1, 74 
83 kDa band from No 
drug lane 
Keratin,  type II cytoskeletal 71, 72, 
73, 1b, 1, 74 738.41 29 56 0.00011 FLEQQNQVLQTK 
type II cytoskeletal 71, 72, 
73, 1b, 1, 74 
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Figure 5.8 CID product ion spectra (A) Doubly protonated peptide specific to subunit alpha-3 at m/z 638.34. (B) Doubly protonated peptide specific to 
subunit alpha-2 at m/z 639.34 (C) Doubly protonated peptide specific to subunit alpha-1 at m/z 760.37.
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5.4. Discussion 
 
The increase in the relative amounts of each tryptic fragment from the (R)-
lacosamide analogue A treated sample compared with (S)-lacosamide analogue A are 
important because whole animal pharmacological studies have demonstrated that the 
anticonvulsant activity is primarily associated with the (R)-stereoisomer. In this chapter, 
several potential candidate target proteins of lacosamide have been identified and 
correspond to the findings in Chapter 4. The 14-3-3 protein family and CRMP2 were 
identified from the mouse brain soluble lysate. The 14-3-3 proteins have the ability to bind 
with more than 100 signalling proteins including protein kinases, phosphatases and 
transmembrane receptors. Examination of the levels of 14-3-3 proteins in the cerebrospinal 
fluid of rats post-seizure demonstrated a significant increase. Specifically, 14-3-3 zeta was 
detected at significant levels from ~25 units to ~150 units in cerebrospinal fluid sampled at 4 
hours after seizure, suggesting that the presence of 14-3-3 zeta within cerebrospinal fluid 
may be a biomarker of acute seizure damage111. This protein family is therefore of significant 
interest as candidate target proteins of the anti-epileptic drug lacosamide. 14-3-3 proteins 
were studied further to identify the sites of modification by (R)-lacosamide analogue A 
(chapter 7).  
Several findings were used to validate preferential modification of CRMP2 by (R)-
lacosamide analogue A. First, MS analysis of the trypsin digest of the modified proteins in 
the ∼62 kDa band indicated that CRMP2 was among the most abundant proteins present in 
this gel slice based on sequence coverage. Second, the enhanced adduction by (R)-
lacosamide analogue A compared with (S)-lacosamide analogue A was confirmed using 
iTRAQ analysis of the tryptic fragments from the ∼62 kDa band. A modest increase (1.3-
fold) in the abundance of CRMP2 fragments was observed in the (R)- lacosamide analogue 
A adduction experiment compared to (S)-lacosamide analogue A reaction when compared to 
a reference protein (tubulin R chain). However, this ratio of iTRAQ data was not significant 
due to their high standard deviation and only one tubulin peptide was a reference peptide. To 
confirm the preference of (R)- and (S)-lacosamide analogue A, the data generated at the 
University of North Carolina using the recombinant GST-CRMP2 demonstrated an increase 
in fluorescent levels (1.5- to 1.8-fold) for both the exogenous ∼82 kDa and the endogenous 
∼62 kDa bands in the (R)-lacosamide analogue A reaction compared with the (S)- 
lacosamide analogue A experiment. Moreover, the progress report on new antiepileptic 
drugs from the Ninth Eilat Conference, indicates that lacosamide demonstrates a novel 
mechanism of action profile by modulating the activity of CRMP2112.  
The sodium/potassium-transporting ATPase family was identified from the mouse 
brain membrane lysate. The sodium/potassium-transporting ATPase catalytic subunit had a 
decreased affinity for K+ in human epileptic cortex113. This protein family is also interesting as 
candidate target proteins of lacosamide.  
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 The results in this Chapter are consistent with the findings in Chapter 4. Moreover, 
they increased the confidence in the significance of candidate target identification by 
revealing  preferential binding  of the (R)-stereoisomer.  
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CHAPTER 6 
Results IV 
Identification of candidate target proteins using 
other (R)-lacosamide analogues 
 
6.1 Introduction 
 
The affinity bait was designed to covalently bind the lacosamide analogue to an 
amino acid in the active site of lacosamide target proteins. No target proteins of lacosamide 
have been reported in the literature, therefore it is unknown which amino acids the drug 
targets in the active site of the target proteins. In this chapter, three different biotinyl 
lacosamide analogues (Figure 6.1) containing different affinity baits were used to enrich 
candidate target proteins of lacosamide.  
 
 
Figure 6.1 Structures of (R)-lacosamide analogues A, B, C and D. 
 
The affinity baits of (R)-lacosamide analogues A, B, C and D are isothiocyanate group, 
epoxy group, azide group and diazirine group respectively. The analogues A and B include 
an electrophilic affinity bait. The electrophilic affinity baits are naturally reactive with 
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nucleophile amino acids, for example lysine and cysteine (Figure 6.2).  Reactivity is 
dependent on pH, time, and temperature.  
 
Figure 6.2 Reaction of electrophilic affinity bait: isothiocyanate (A), epoxy (B). Figure 
provided by Steve Cotton. 
 
Labelling a protein at a specific nucleophilic side-chain is not possible when there are no 
nucleophilic amino acids in proximity of the binding site. Therefore, (R)-lacosamide 
analogues C and D were designed by Prof. Kohn and his colleagues. They contained a 
photoreactive affinity bait, which is activated by exposure to light. They can form a covalent 
bond through addition reaction with any amino acid side-chain or peptide backbone114 
(Figure 6.3). 
 
 
Figure 6.3 Reaction of photoreactive affinity baits after light activation. Azide (A), 
diazine (B). Figure provided by Steve Cotton. 
 
Aryl azide forms the singlet nitrene by photolysis and rapidly rearranges by ring expansion to 
form a dehydroazepine. Dehydroazepines react preferentially with nucleophiles. Exposure of 
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diazine to UV light results in the formation of a reactive carbine, with the release of nitrogen. 
The activated carbene has a very short half-life, so reactions must occur with groups in a 
very close proximity. 
 
6.2 Identification of candidate target proteins using biotinyl (R)-lacosamide 
analogue B 
 
The biotinyl (R)-lacosamide analogue B contains an epoxide group, an electrophilic 
affinity bait, which is similar to analogue A. Unlike previous studies with the analogue A 
which identified candidate lacosamide targets from mouse brain lysate, the studies reported 
in this Chapter used rat brain lysate. Whole rat brain lysate was fractionated as outlined in 
Figure 6.4 to yield the cytosolic portion. This rat brain cytosolic fraction was then labelled 
with biotinyl (R)-lacosamide analogue B and no drug (control). The adducted cytosolic 
fraction was further fractionated by ammonium sulphate precipitation and strong anion 
exchange (SAX; Q-Sepharose). A portion of each SAX fraction was reacted with rhodamine 
probe, separated by SDS-PAGE and scanned for fluorescence. Only one fraction which was 
obtained from the 45-55 % ammonium sulphate cut and eluted from the SAX column 
between 200-300 mM sodium chloride showed fluorescence and exhibited preference for 
(R)- rather than (S)-lacosamide analogue B (Figure 6.5).  
 
 
 
Figure 6.4 Sample preparation for biotinyl (R)-lacosamide analogue B study. Rat brain 
lysate was homogenized and sequentially centrifuged to obtain the cytosolic fraction. Figure 
provided by Pierre Morieux.  
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Figure 6.5 The rhodaminyl (R)- and (S)-lacosamide analogue B labeled proteins from 
the 45-55 % ammonium sulphate cut of cytosolic fraction of rat brain lysate were 
detected by in-gel fluorescence. All images are shown in gray scale. The 45 kDa band 
shows preference of (R)-enantiomer. Figure provided by Pierre Morieux. 
 
To identify proteins in the same SAX fraction, the sample was incubated with the biotinyl (R)-
lacosamide analogue B and no drug (control). The modified fraction was then treated with 
biotinyl probe. These studies were undertaken by Pierre Morieux in the laboratory of Prof. 
Harold Kohn at the University of North Carolina and the beads were sent to Manchester. On-
bead tryptic digestion and LC-MS/MS analysis was performed as previously described. Only 
creatine kinase B-type was identified from this fraction (Table 6.1). This protein has been 
identified before using (R)-lacosamide analogue A in Chapter 4.  No proteins were identified 
in the control. The CID mass spectra of some creatine kinase B-type peptides are shown in 
Figure 6.6. In this experiment, the false positive rate was estimated at 3.2% approximately, 
which was acceptable because it was less than 5%, the maximum acceptable rate for 
general proteomics studies. Further work was undertaken to identify sites of modification on 
this protein and this is described in chapter 7. 
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Table 6.1 LC-MS/MS Mascot results from on-bead trypsin digestions of rat brain lysate after enriched by biotinyl (R)-lacosamide analogue B. 
Significant peptide score was 30 (p<0.05). False discovery rate was approximately 3.2%. 
 
 
Protein identification Protein score Observed m/z ppm Ion score 
Expectation 
value Sequence Isoforms 
Creatine kinase B-type 269 516.30 49 38 0.013  LLIEMEQR B-type 
  801.94 33 84 2.90E-07  LAVEALSSLDGDLSGR B-type 
  841.94 28 59 7.50E-05  LEQGQPIDDLMPAQK B-type 
  925.01 25 88 1.00E-07  LGFSEVELVQMVVDGVK B-type 
 
“ppm” refers to the difference between observed precursor ion mass and expected for the identified peptide. 
“Expectation value” refers to the number of times that expect to obtain this score or better by chance. 
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Figure 6.6 CID product ion spectra (A) Doubly protonated creatine kinase B-type peptide at m/z 801.94. (B) Doubly protonated creatine kinase B-type 
peptide at m/z 925.01.  
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6.3 Identification of candidate target proteins using biotinyl (R)-lacosamide 
analogue C 
 
The biotinyl (R)-lacosamide analogue C contains a photoreactive affinity bait, which 
is activated by exposure to light. It can form covalent bonds through addition reaction with 
any amino acid. The analogue C was used to identify candidate target proteins from whole 
mouse brain lysate, similar to the on-bead digestion studies performed with analogue A 
reported in chapter 4. The (R)-lacosamide analogue C and no drug (control) lysate adduction 
were prepared, and the modified lysate treated with the biotinyl probe. Biotinylated proteins 
were captured with streptavidin beads, the beads stringently washed to remove background 
proteins adsorbed on the resin. These studies were undertaken by Ki Duk Park in the 
laboratory of Prof. Harold Kohn at the University of North Carolina and the beads were sent 
to Manchester. On-bead tryptic digestion and LC-MS/MS analysis was performed as 
previously described. Data were processed and analysed as previously outlined (Table 6.2).  
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Table 6.2 LC-MS/MS Mascot results from on-bead trypsin digestions of mouse brain lysate after enriched by biotinyl (R)-lacosamide analogue C. 
Significant peptide score was 27 (p<0.05). False discovery rate was approximately 2.9%. 
 
Protein identification Protein 
score 
Observed 
m/z 
ppm Ion 
score 
Expectation 
value Sequence Isoforms 
Sodium/potassium-transporting ATPase subunit alpha-3 373 414.25 52 30 0.038  AAVPDAVGK subunit alpha-1, 2, 3 
  437.26 51 41 0.0055  GVVVATGDR subunit alpha-3 
  520.80 32 50 0.00036  GGQDNIPVLK subunit alpha-3 
  579.84 14 48 0.00083  IATLASGLEVGK subunit alpha-3 
  618.85 11 51 0.00031  LNIPVSQVNPR subunit alpha-2,3 
  915.47 15 69 5.10E-06  GVGIISEGNETVEDIAAR subunit alpha-1,2,3 
  936.51 27 44 0.0015  MQVNAEEVVVGDLVEIK subunit alpha-3 
  822.09 31 40 0.0027  QAADMILLDDNFASIVTGVEEGR subunit alpha-1,2,3,4 
Sodium/potassium-transporting ATPase subunit alpha-1 180 414.25 52 30 0.038  AAVPDAVGK subunit alpha-1, 2, 3 
  915.47 15 69 5.10E-06  GVGIISEGNETVEDIAAR subunit alpha-1,2,3 
  822.09 31 40 0.0027  QAADMILLDDNFASIVTGVEEGR subunit alpha-1,2,3,4 
  945.48 23 41 0.0021 EQPLDEELKDAFQNAYLELGGLGER subunit alpha-1 
ATP synthase subunit beta 119 961.50 22 57 7.80E-05  DQEGQDVLLFIDNIFR subunit beta 
  892.48 26 62 1.70E-05  SLQDIIAILGMDELSEEDKLTVSR subunit beta 
Creatine kinase B-type 102 801.94 34 45 0.0013  LAVEALSSLDGDLSGR B-type 
  925.01 27 57 7.30E-05  LGFSEVELVQMVVDGVK B-type 
Clathrin heavy chain 1 87 974.03 29 56 0.0001  AFMTADLPNELIELLEK 1 
  961.19 21 31 0.021  RPLIDQVVQTALSETQDPEEVSVTVK 1 
14-3-3 protein epsilon 90 408.73 53 38 0.01  LAEQAER Epsilon, theta, beta-alpha, zeta-delta, gamma, eta, sigma 
  1086.89 21 52 0.00013  AAFDDAIAELDTLSEESYKDSTLIMQLLR epsilon 
2',3'-cyclic-nucleotide 3'-phosphodiesterase 72 437.58 55 32 0.024  VLVLDDTNHER - 
  823.95 27 40 0.004  DFLPLYFGWFLTK - 
 
 
“ppm” refers to the difference between observed precursor ion mass and expected for the identified peptide. 
“Expectation value” refers to the number of times that expect to obtain this score or better by chance. 
“ – “ means that no isoform specified. 
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Seven candidate target proteins were observed, whilst only human keratin was found in the 
no drug control. This result showed the potential of analogue C to enrich candidate target 
proteins. All of the proteins that were identified using biotinyl (R)-lacosamide analogue C 
were also identified using (R)-lacosamide analogue A (section 4.4 in Chapter 4). According 
to this preliminary experiment, the result from analogue C supported the findings from 
analogue A. In a separate experiment, the on-bead digested sample was separated by SCX 
chromatography prior to LC-MS/MS in order to increase the number of peptides identified 
(Table 6.3). For SCX chromatography, 20 fractions were collected over a 30 min linear 
gradient using the following mobile phases: A, 20 % (v/v) acetonitrile, 0.1 % (v/v) formic acid; 
B, 20 % (v/v) acetonitrile, 0.1 % (v/v) formic acid, 1 M potassium chloride. As demonstrated 
with analogue A (section 4.4 in Chapter 4), SCX fractionation improved the number of 
identified candidate target proteins, in this case from seven to fourteen. Although, SCX and 
reversed phase liquid chromatography separations were coupled to increase the separation 
power and dynamic range of analysis,  none of these proteins was identified in the control, 
similar to the previous experiment. All of the candidate target proteins which were identified 
using analogue C were also found using analogue A (section 4.4 in Chapter 4).  Like biotinyl 
(R)-lacosamide analogue A, analogue C is also suitable for identifying candidate target 
proteins of (R)-lacosamide. However, there were sixteen candidate target proteins identified 
with analogue A that were not seen with analogue C.  
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Table 6.3 LC-MS/MS Mascot results from on-bead trypsin digestions and SCX separation of mouse brain lysate after enriched by biotinyl (R)-
lacosamide analogue C. Significant peptide score was 28 (p<0.05). False discovery rate was approximately 3.4%. 
 
Protein identification Protein score 
Observed 
m/z ppm Ion score 
Expectation 
value Sequence Isoforms 
Sodium/potassium-transporting ATPase subunit alpha-3 485 431.76 28 37 0.01 LIFDNLK subunit alpha-1,2,3,4 
  495.81 29 32 0.053 LIFDNLKK subunit alpha-1,2,3,4 
  618.87 34 80 6.70E-07 LNIPVSQVNPR subunit alpha-2,3 
  634.87 26 33 0.027 NMVPQQALVIR subunit alpha-1,2,3,4 
  638.35 48 89 6.20E-08 DVAGDASESALLK subunit alpha-3 
  915.48 24 104 1.90E-09 GVGIISEGNETVEDIAAR subunit alpha-1,2,3 
  936.51 27 110 4.40E-10 MQVNAEEVVVGDLVEIK subunit alpha-3 
Glyceraldehyde-3-phosphate dehydrogenase 266 814.50 33 43 0.0062 LVINGKPITIFQER - 
  890.42 29 71 2.60E-06 LISWYDNEYGYSNR - 
  1146.05 23 152 2.30E-14 WGEAGAEYVVESTGVFTTMEK - 
Creatine kinase B-type  652.38 32 44 0.0024 VLTPELYAELR B-type 
  801.94 33 85 1.90E-07 LAVEALSSLDGDLSGR B-type 
14-3-3 protein zeta/delta 
156 
454.28 46  37 0.012 NLLSVAYK 
zeta-delta, theta, beta-
alpha, gamma, eta, epsilon, 
sigma 
 
 
595.35  39 36 0.038 DSTLIMQLLR 
zeta-delta, theta, beta-
alpha, gamma, eta, epsilon, 
sigma 
  1021.01 19 83 1.80E-07 GIVDQSQQAYQEAFEISK zeta/delta 
Fructose-bisphosphate aldolase C 87 826.99 33 87 1.50E-07 TPSALAILENANVLAR C 
Fructose-bisphosphate aldolase A 114 666.87 35 75 1.50E-06 GILAADESTGSIAK A 
  448.26 52 39 0.011 ADDGRPFPQVIK A 
Malate dehydrogenase mitochondrial precursor 109 727.87 29 36 0.035 AGAGSATLSMAYAGAR mitochondrial precursor 
  780.92 30 73 6.40E-06 VDFPQDQLATLTGR mitochondrial precursor 
ADP/ATP translocase 1 141 585.31 46 31 0.039 EQGFLSFWR 1 
  610.36 47 29 0.095 DFLAGGIAAAVSK 1 
  723.89 31 81 9.70E-07 YFPTQALNFAFK 1,2,4 
Dihydropyrimidinase-related protein 2 86 863.43 32 53 0.0002 MDENQFVAVTSTNAAK 1,2,3 
  958.50 22 33 0.022 ISVGSDADLVIWDPDSVK 2 
ATP synthase subunit alpha 80 586.34 47 36 0.029 VVDALGNAIDGK subunit alpha 
  812.97 36 44 0.0026 TGAIVDVPVGEELLGR subunit alpha 
Clathrin heavy chain 86 586.98 38 38 0.0064 KFNALFAQGNYSEAAK 1 
  895.98 25 48 0.0005 YESLELCRPVLQQGR 1 
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Table 6.3 (cont.) LC-MS/MS Mascot results from on-bead trypsin digestions and SCX separation of mouse brain lysate after enriched by biotinyl 
(R)-lacosamide analogue C. Significant peptide score was 28 (p<0.05). False discovery rate was approximately 3.4%. 
 
Protein identification Protein score 
Observed 
m/z ppm Ion score 
Expectation 
value Sequence Isoforms 
14-3-3 protein epsilon 
104 
454.28 46 37 0.012  NLLSVAYK 
zeta-delta, theta, beta-
alpha, gamma, eta, epsilon, 
sigma 
  554.84 49 31 0.076  LKMIREYR epsilon 
 
 
595.35 39 36 0.038  DSTLIMQLLR 
zeta-delta, theta, beta-
alpha, gamma, eta, epsilon, 
sigma 
Sodium/potassium-transporting ATPase subunit alpha-1 248 431.76 28 37 0.01 LIFDNLK subunit alpha-1,2,3,4 
  495.81 29 32 0.053 LIFDNLKK subunit alpha-1,2,3,4 
  634.87 26 33 0.027 NMVPQQALVIR subunit alpha-1,2,3,4 
  915.48 24 104 1.90E-09 GVGIISEGNETVEDIAAR subunit alpha-1,2,3 
  945.48 22 42 0.0011 EQPLDEELKDAFQNAYLELGGLGER subunit alpha-1 
2',3'-cyclic-nucleotide 3'-phosphodiesterase 79 437.57 36 34 0.0081 VLVLDDTNHER - 
  823.95 27 45 0.0007 DFLPLYFGWFLTK - 
 
“ppm” refers to the difference between observed precursor ion mass and expected for the identified peptide. 
“Expectation value” refers to the number of times that expect to obtain this score or better by chance. 
“ – “ means that no isoform specified. 
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6.4 Identification of candidate target proteins using biotinyl (R)- lacosamide 
analogue D 
 
The (R)-lacosamide analogue D includes a photoreactive affinity bait similar to 
analogue C.  Mouse brain soluble lysate was used for this study. The enriched target 
proteins using (R)-lacosamide analogue D and no drug (control) were prepared as in the 
previous experiments. These studies were undertaken by Christophe Salome in the 
laboratory of Prof. Harold Kohn at the University of North Carolina and the beads were sent 
to Manchester. On-bead tryptic digestion and LC-MS/MS analysis was performed as 
previously described. Data were processed and analysed as previously outlined These 
experiments identified a single candidate target protein, synapsin-1 which was not identified 
using any previous (R)-lacosamide analogues (Table 6.4). There was also evidence of 
incomplete tryptic digestion as arginine residues were present in the middle of the peptide 
sequences.  The observation of incomplete tryptic digestion was possibly attributable to the 
low quantities of protein and trypsin proteolysis may not access the protein properly. 
However, the CID mass spectra of synapsin-1 peptides were significant and acceptable to 
identify synapsin-1 as a candidate target protein (Figure 6.7). No proteins were identified in 
the control. The photoreactive affinity bait of analogue D was therefore able to identify a 
novel interesting candidate target protein of lacosamide. 
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Table 6.4 LC-MS/MS Mascot results from on-bead trypsin digestions and SCX separation of mouse brain lysate after enriched by biotinyl (R)-
lacosamide analogue D.  Significant peptide score was 30 (p<0.05). False discovery rate was approximately 3.8%. 
 
Protein identification Protein 
score 
Observed 
m/z 
ppm Ion 
score 
Expectation 
value Sequence Isoform 
Synapsin 1 130 495.62 47 59 6.50E-05 QGPPQKPPGPAGPTR 1 
  812.11 29 36 0.023 QGPPQKPPGPAGPTRQASQAGPGPR 1 
  831.12 31 35 0.034 ASGAPPGGQQRQGPPQKPPGPAGPTR 1 
 
“ppm” refers to the difference between observed precursor ion mass and expected for the identified peptide. 
“Expectation value” refers to the number of times that expect to obtain this score or better by chance. 
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Figure 6.7 CID product ion spectra (A) Triply protonated Synapsin 1 peptide at m/z 495.62. (B) Triply protonated Synapsin 1 peptide at m/z 831.12.   
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6.5 Discussion 
 
 In this chapter, tryptic on-bead digestion was used to identify candidate target 
proteins of lacosamide using three different analogues, each of which contained a different 
affinity bait. Every experiments were carried out in triplicate for improved confidence of the 
data for identification. The reported peptides were observed in all three experiments and had 
an ion score above significant score at 95% confidence.  
The first study changed from mouse to rat brain lysate because the rat brain lysate is 
more complex than mouse. Rat genome (2.75 billion base pairs) is smaller than the human 
genome (2.9 billion base pairs) and slightly larger than mouse genome (2.6 billion base 
pairs). The rat genome contains about the same number of genes as the human. Almost all 
human genes known to be associated with diseases appearing in the rat genome. The rat is 
an excellent model for many areas of medical research115. The biotinyl (R)-lacosamide 
analogue B, which contains an electrophilic affinity bait was used to identify candidate target 
proteins from cytosolic enriched fractions of rat brain lysateIn these experiments, creatine 
kinase B-type was identified after biotin-streptavidin enrichment. This protein has been 
identified before using analogue A. The results using analogue B were inconsistent with 
those using analogue A because only creatine kinase B-type was identified. It is possible 
that more candidate targets could be enriched from other rat brain fractions. Creatine kinase 
is a protein expressed by various tissues and cell types, especially cells that consume ATP 
rapidly. Creatine kinase catalyses the conversion of creatine and consumes ATP to create 
phosphocreatine and ADP. It also catalyses the reverse reaction, generating ATP from 
phosphocreatine and ADP. Seizure patients’ serum levels of creatine kinase were 
significantly higher than four hours after seizure; serum creatine kinase measurements is 
reported to be a potentially useful laboratory test to differentiate seizure  from  syncope (loss 
of consciousness resulting from insufficient blood flow to the brain)116. This protein may be a 
potential target of lacosamide drug.  
Secondly, the biotinyl (R)-lacosamide analogue C contains photoreactive affinity 
bait. It can form covalent bonds through addition reaction with any amino acid. This analogue 
was used to identify target protein from whole mouse brain lysate. All target proteins which 
were identified from the analogue C were also previously found using analogue A.  Biotinyl 
(R)-lacosamide analogue C therefore also supports the findings from analogue A. However, 
sixteen candidate target proteins were identified with analogue A but were not seen with 
analogue C. Aryl azides may not have been the best choice for a photoreactive group. 
Dehydroazepine and singlet nitrene are unstable and react very slowly and preferentially 
with nucleophile. This preference resulted in similar finding to the analogue A. The 
dehydroazepine and singlet nitrene also have ability to react with water, a key competitor of 
the photoaffinity labeling reaction 117. This may explain why  fewer protein identifications 
were made than with the analogue A. 
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Finally, the (R)-lacosamide analogue D contains a diazirine group, which was used 
as a photoreactive affinity bait to enrich targets from mouse brain soluble lysate.  Synapsin-1 
was identified in this way. This protein has not been identified using any previous (R)-
lacosamide analogues. Reasons for this finding may be that synapsin-1 does not have lysine 
or cysteine in the binding site or they are difficult to reach and react with electrophilic affinity 
baits. The photoreactive affinity bait which reacts non-selectively to any amino acid should 
be able to bind with this protein. However, aryl azide group from analogue C prefers 
nucleophiles 117. It yielded similar finding with the electrophilic affinity bait. The diazirine 
group from analogue D can generate carbenes that are more reactive to C-H bonds than 
nitrenes due to synapsin-1 binding118.  The synapsins are a family of proteins that are 
involved in the regulation of neurotransmitter release at synapses.  Double knock-out mice 
lacking synapsins I and II are epileptic119. Therefore, synapsin-1 is an interesting candidate 
target protein because it is probably involved in epilepsy However, enriching candidate 
targets by (R)-lacosamide analogue D had fewer protein identifications. This might be 
attributable to the poor efficiency of reaction of the diazirine group with nucleophillic amino 
acids. A compound containing both isothiocyanate and diazirine group (isothiocyanate cross-
linker, 3-trifluoromethyl-3-m-isothiocyanophenyldiazirine) has been linked covalently to 
erythrocyte membrane proteins through the isothiocyanate; however, linkage via the 
diazirine moiety was not observed120. This showed the isothiocyanate group is more reactive 
to proteins than the diazirine group. A diazirine group can react with phospholipids and 
steroids in cell lysate121. The diazirine photolabel (40–50%) was incorporated into the 
phospholipids and cholesterol components of the membrane, whereas low labelling 
efficiency (0.01–1.2%) was observed for internal segments of proteins122. In conclusion, the 
(R)-lacosamide analogues A, B and C provided consistent protein identifications. (R)-
lacosamide D which contains a diazirine group, produced different evidence of protein 
identification.   Thus it may be argued that analogue A has been of most use in identifying 
candidate target proteins for lacosamide. 
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CHAPTER 7 
Results V 
Identification of modification sites of candidate 
target proteins 
 
 
7.1 Introduction 
 
 None of the previous studies identifying candidate target proteins of lacosamide 
using drug analogues identified modified peptides. Most samples were prepared using on-
bead digestion because it simplifiesd the procedure and avoids the possibility of mis- 
identification of low concentration proteins. However, the immobilized streptavidin (a protein 
from Streptomyces avidinii) used for enrichment of the biotin analogues, can also be 
digested by trypsin. All of the on-bead digest analyses showed that the most abundant 
peptides in the samples were streptavidin peptides. The lack of detection of modified 
peptides may suggest inferior response factors for the modified peptides so that detection 
will be enhanced by an additional stage of enrichment. This chapter describes the 
development of methodology to enrich peptides containing the biotinyl (R)-lacosamide 
analogue and the analysis of their sites of modification using various MS fragmentation 
techniques.  
 
7.2 Enrichment of biotinyl (R)-lacosamide analogue modified peptides 
 
  Streptavidin beads have been used to enrich peptides containing the biotinyl 
(R)-lacosamide analogue. There is strong affinity between streptavidin and biotin: indeed it is 
reported to be the strongest non-covalent binding known in nature 123. Therefore, to elute the 
biotinylated peptides from the streptavidin affinity column, an MS compatible method was 
developed.  A 50:50 mixture of unmodified neurotensin peptide and neurotensin modified by 
biotinyl (R)-lacosamide analogue A was used as a model to develop these methods. The 
peptide mixture was incubated with streptavidin beads and unbound (non-biotinylated) 
peptides washed off. The biotinylated peptides remained on the beads. Several methods 
were examined for optimal elution of the biotinylated peptides from the streptavidin beads. 
Most of the methods tested rely on denaturation of the three dimensional structure of 
streptavidin, for example using a chaotrope at low pH (2 M urea in 0.1 M glycine-HCL pH 2.9 
or 8 M guanidine HCl pH 1.5), using salt to disrupt salt bridges in proteins (150 mM 
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ammonium chloride, 10 mM ammonium phosphate pH 7.0) and using high temperature (heat 
at 95oC with 0.01% (w/w) octyl glycoside). These elution methods were not effective in 
eluting the bound biotinylated peptides. Therefore a competitive elution approach (1 mM 
biotin in 50 % (v/v) acetonitrile and 0.1 % (v/v) formic acid) to promote peptide release was 
tested. The technique works because the excess biotin in the elution buffer displaces the 
biotinylated peptides from the streptavidin beads. Elution in this manner enabled enrichment 
of biotinylated peptides. However, MS analysis gave evidence of interference from biotin 
related peaks arising from the elution buffer. Therefore, SCX chromatography was used to 
remove excess biotin (Figure7.1). Before enrichment, the doubly and triply protonated 
unmodified neurotensin at m/z 836.9 and 558.2 could be observed, and the doubly and triply 
protonated forms of neurotensin modified with (R)-lacosamide analogue A could also be 
observed at m/z 1224.4 and 816.7 respectively.  The elent from the streptavidin beads 
showed doubly protonated modified neurotensin at m/z 1224.4 and biotin related peaks from 
m/z 500 to 1000. These biotin related peaks were removed into the wash fraction of the SCX 
clean-up step. The mass spectrum of the SCX wash fraction was similar to the biotin elution 
buffer (Figure 7.2). They showed singly charged ions attributable to multimers of biotin and 
their alkali metal-ionised analogues. Finally, only triply protonated neurotensin modified with 
(R)-lacosamide analogue A at m/z 816.7 could be observed after streptavidin enrichment 
and SCX chromatography. The observation of the triply charged ion after enrichment, but the 
double charged ion before enrichment due to reduced competition for ionising protons in the 
simpler mixture. The same protocol was therefore applied to the tryptic digest of enolase 
modified with (R)-lacosamide analogue A which is a more complex mixture (Figure 7.3). 
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Figure 7.1 ESI-QToF mass spectra of the biotinyl (R)-lacosamide analogue A attached to neurotensin (A) neurotensin modified with (R)-lacosamide 
analogue A before enrichment (B) eluate from streptavidin beads (C) wash from SCX clean-up (D) eluate from streptavidin beads (in B) following SCX clean-
up, [M+2H]2+ and [M+3H]3+ refer to doubly and triply protonated unmodified neurotensin, respectively. [M*+2H]2+ and [M*+3H]3+ refer to doubly and triply 
protonated neurotensin modified with (R)-lacosamide analogue A, respectively. 
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Figure 7.2 ESI-QToF mass spectra of the biotin elution buffer and wash from the scx 
clean-up of the neurotensin modified with (R)-lacosamide analogue A (A) Biotin elution 
buffer (B) wash from SCX clean-up. [2M+H]+, [3M+H]+ refer to singly protonated biotin 
multimers.  
 
Figure 7.3 ESI-QToF mass spectra of the biotinyl (R)-lacosamide analogue A attached 
to enolase. Digested modified enolase was analysed (A) before enrichment and (B) after 
elution from streptavidin bead and SCX clean-up. * refers to doubly or triply protonated 
enolase modified with (R)-lacosamide analogue A peptides. 
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The number of observed biotinylated peptides dramatically increased after enrichment, with 
the unmodified peptides at background level. The sequence of all the biotinylated peptides 
was confirmed by CID yielding characteristic fragmented ions of biotinyl (R)-lacosamide 
analogue A. This result demonstrates that the developed method effectively enriches 
modified peptides, increasing the likelihood of identifying biotinylated peptides from the 
potential target proteins. These enriched enolase peptides were investigated further to obtain 
information about the modified residues using a combination of peptide fragmentation 
techniques. 
 
7.3 Using CID and ETD to determine peptide sequences and the sites of 
modification. 
 
 In chapter 3, the CID of enolase peptides containing biotinyl (R)-lacosamide 
analogue A was studied using a Q-ToF instrument. The characteristic fragment ions of the 
analogue A were much more abundant than peptide-derived b and y ions. All sequence-
related fragment ions demonstrated loss of the lacosamide analogue and there was no mass 
spectrometric evidence for the site of modification (Figure 3.10B). ETD was therefore 
evaluated for the purpose of defining the site of modification. As described in the 
Introduction, ETD is a method to fragment peptides that utilizes ion/ion chemistry. It 
fragments peptides by transferring an electron from a radical anion to a protonated peptide. 
This induces fragmentation of the peptide backbone whilst retaining labile modifications at 
the site of attachment. The biotinylated enolase peptides were fragmented by ETD using a 
high capacity ion trap instrument (Bruker, Coventry, UK), yielding distinct fragmentation 
patterns.  
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Figure 7.4 Product ion spectra of doubly protonated enolase peptide IATAIEKK modified with lacosamide A, at m/z 825.2, using the Amazon ion 
trap instrument. (A) CID product ion mass spectrum (B) ETD product ion mass spectrum, [M+H]+ and [M+2H]2+ refer to singly and doubly protonated 
unmodified IATAIEKK, respectively. [M*+H]+ and [M*+2H]2+ refer to singly doubly protonated modified IATAIEKK, respectively. c* and z* refer to fragment ions 
containing biotinyl (R)-lacosamide analogue A. 
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Figure 7.4 shows the CID and ETD analysis of the same biotinyl (R)-lacosamide analogue A 
modified enolase peptide as in Figure 3.10. However, these data were acquired using the 
HCT Ultra high capacity ion trap instrument (Bruker, Coventry, UK). The characteristic ions 
of biotinyl (R)-lacosamide analogue A (m/z 455.2, 483.2, 501.2, 734.4 and 776.3) and the 
singly protonated biotinyl (R)-lacosamide analogue A modified enolase peptide partially 
fragmented masses of ([M+H]++ 42,  (M+H]++ 164 and ([M+H]++ 292) were observed in the 
CID tandem mass spectrum. These patterns were found for every enolase peptide 
containing the biotinyl (R)-lacosamide analogue. In the ETD product ion spectra, all of the 
sequence related fragment ions retained the biotinyl (R)-lacosamide analogue A. Singly 
protonated enolase peptide containing fragmented masses of biotinyl (R)-lacosamide 
analogue A were also observed in the ETD  spectrum. These patterns were similar for every 
peptide containing the biotinyl (R)-lacosamide analogue ETD. Although ETD fragmentation is 
able to provide information about the site of modification, in this case few sequence related 
fragment ions could be observed. In conclusion, neither the CID or ETD methods of 
fragmentation generated sufficient information to determine both the sequence and the sites 
of modification of unknown peptides. CID tandem mass spectrometry provided sequence 
related ions in very low signal intensities. The characteristic ions of biotinyl (R)-lacosamide 
analogue were the most abundant. It was difficult to distinguish b and y ions of unknown 
peptides from the background noise. This finding was observed in both in-space (Q-ToF) 
and in-time (ion trap) MS/MS platforms. ETD tandem mass spectra provided a few sequence 
related fragment ions of unknown peptides. However, they are not enough to deduce the 
sequence of the modified peptide from mouse brain proteins. The ETD analysis still needs 
more optimization before applying to use for whole lysate experiments.  
 
7.4 Identify modification sites using purified protein and AB-(R)-lacosamide 
analogue without biotin 
 
As it was very difficult to identify the modification sites in a large screen, the 
modification was performed in vitro using purified protein and AB-(R) lacosamide analogue A 
without biotin. The analogue A without biotin (307.1 Da) has a substantially lower  molecular 
weight than the biotinyl (R)-lacosamide analogue A (775.9 Da). 14-3-3 zeta protein, a 
candidate target of lacosamide identified by analogue A, is commercially available. 
Recombinant human 14-3-3 zeta protein expressed in E. coli was reacted with a 10 fold μM 
excess of AB-(R)-lacosamide analogue A. This preparation was undertaken by Ki Duk Park 
at the University of North Carolina and the samples were sent to Manchester. The modified 
and unmodified 14-3-3 zeta proteins were subjected to intact protein analysis and digested 
with trypsin followed by LC-MS/MS analysis using a Q-ToF Global instrument. For intact 
protein analysis, unmodified 14-3-3 zeta protein and modified 14-3-3 zeta protein could be 
observed from the ESI-QToF deconvoluted mass spectrum (Figure 7.5). The mass of 
modified 14-3-3 zeta protein suggested concomitant oxidation of methionine (~16 Da).  For 
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tryptic digest analysis, observed ions along the chromatograms were compared between 
unmodified and modified 14-3-3 zeta digests. An ion at m/z 618.29 appeared in the modified 
14-3-3 zeta digest chromatogram but was not observed in the unmodified 14-3-3 zeta digest 
chromatogram. The ion at this m/z was therefore fragmented by CID to obtain a product ion 
spectrum (Figure 7.6). The spectrum showed a number of sequence related ions, some of 
which contained the mass of AB-(R)-lacosamide analogue A.  The spectrum did not show 
the fragmented ions of lacosamide analogue; this may be attributed to the greater relative 
abundances of the ions. Using a smaller analogue, both the sequence and the modification 
site could be determined in a single CID experiment.  K120 was identified as the site of AB-
(R)-lacosamide analogue A modification on 14-3-3 zeta protein. The 14-3-3 proteins are 
binding proteins that have been shown to interact with a wide array of enzymes involved in 
primary biosynthetic and energy metabolism. The significance of binding of the 14-3-3 
protein on glyceraldehyde 3-phosphate dehydrogenase, glutamine synthetase 1 and 
glutamine synthetase 2 are S126, S115 and S95, respectively124. K120 is in a functional area 
of the 14-3-3 protein. The finding supports the possibility that the 14-3-3 protein is a potential 
target protein of (R)-lacosamide drug. 
 
 
Figure 7.5 ESI-QToF deconvoluted mass spectra of the unmodified 14-3-3 protein zeta 
(A). modified 14-3-3 protein zeta by (R)-lacosamide analogue A (B). M and M* refer to 
unmodified 14-3-3 protein zeta and modified 14-3-3 protein zeta, respectively. 
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Figure 7.6 Product ion spectrum of doubly protonated modified 14-3-3 zeta peptide 
(VFYLKMK) at m/z 618.29. [M+H]+ refers to singly protonated modified VFYLKMK, 
unmodified b and y refer to fragmented ions, b* and y* refer to fragmented ions containing 
(R)-lacosamide analogue A.  
 
Protein data bank provides a crystal structure of the quaternary structure of 14-3-3 protein 
zeta consist of four monomers of Bos taurus expressed from Escherichia coli containing 4 
domains125. The sequences of 14-3-3 protein zeta from human and Bos taurus are similar. 
K120 was mapped to the crystal structure (Figure 7.7). It showed that this residue is not on 
the surface of the protein. This suggests that the drug did not bind to K120 simply as a result 
of ease of access. The adduction reaction was conducted under conditions that were not 
expected to result in denaturing of the three-dimensional structure. 
 
Figure 7.7 3D-model of the quaternary structure of 14-3-3 protein zeta consist of four 
monomers. K120 was modified by (R)-lacosamide analogue A. 
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 Following the success of using a smaller lacosamide analogue, other interesting 
candidate target proteins of lacosamide were overexpressed in E.coli.  In chapter 4 and 5, 
CRMP2 was identified as a potential lacosamide target protein and showed preference of 
(R)- than (S)-lacosamide analogue A.  CRMP2 was therefore recombinantly expressed in E. 
coli and adducted with 250 fold μM excess of AB-(R)-lacosamide analogue A without biotin 
(307.1 Da). This preparation was undertaken by Steve Cotton at the University of North 
Carolina and the samples were sent to Manchester. The samples were subject to trypsin 
digestion and analysed by LC-MS/MS. Observed ions throughout the LC-MS analysis were 
compared between unmodified and modified CRMP2 digests. Ions at m/z 535.24 were 
observed in the analysis of the modified CRMP2 digest chromatogram but not in the 
unmodified CRMP2 digest. Ions of m/z 535.24 were therefore fragmented by CID to obtain 
product ion spectra (Figure 7.8).  
 
 
Figure 7.8 Product ion spectrum of triply protonated modified CRMP2 peptide 
(KPFPDFVYKR) at m/z 535.24. b* and y* refer to fragment ions containing (R)-lacosamide 
analogue A.  
 
The product ion spectrum provided sufficient information to identify both the peptide 
sequence and the site of modification. K472 was modified by AB-(R)-lacosamide analogue 
A. Protein data bank provides a crystal structure of the human CRMP2 expressed from E. 
coli containing four monomers. K472 was mapped to the crystal structure (Figure 7.9).  
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Figure 7.9 3D-model of the quaternary structure of CRMP2 consist of four monomers. 
K472 was modified by (R)-lacosamide analogue A. 
 
K472 has not been implicated in specific protein functions, but it is in a region that is very 
close to areas implicated in binding to calcium channels (479-500)126, calmodulin (475-493), 
and GAP activity for stimulating tubulin GTP hydrolysis (480-509)127. The modification of a 
residue near the functional site increases the interest in this candidate target and 
pharmaceutical studies by the collaborators in this project are in progress to confirm this 
candidate. 
 In chapter 6, creatine kinase B-type was identified as a potential lacosamide target 
protein following on-bead digestion using biotinyl (R)-lacosamide analogue B enrichment.  
Creatine kinase B-type was therefore recombinantly expressed in E. coli and 60 μg was 
adducted with 5, 50, 500 fold μM and 5 fold mM excess of AB-(R)-lacosamide analogue B 
without biotin (330.1 Da) This preparation was undertaken by Pierre Morieux at the 
University of North Carolina and the samples were sent to Manchester. The modified and 
unmodified forms of creatine kinase B-type were subjected to intact protein analysis and 
digested with trypsin followed by LC-MS/MS analysis using a Q-ToF Global.  For intact 
protein analysis, unmodified creatine kinase B-type was clearly observed in the 
deconvoluted mass spectra of unmodified and 5-500 μM modified creatine kinase B-type 
(Figures 7.10A to D). These showed incomplete modification of creatine kinase B-type using 
of AB-(R)-lacosamide analogue B up to 500 μM. Resolution of the deconvoluted mass 
spectrum in Figure 7.10C was poor resulting from the low signal to noise of protonated 
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protein ion. The modified creatine kinase B-type could be observed from the deconvoluted 
mass spectra of 500 μM and 5 mM modified creatine kinase B-type. (Figure 7.10D and F).  
Most of protein seemed to be modified using 5 mM AB-(R)-lacosamide analogue B. Di- and 
tri- adduction of creatine kinase B-type were also observed at this concentration of reagent. 
For the tryptic digest analysis, observed ions during LC-MS were compared between 
unmodified and modified creatine kinase B-type digests. Ions at m/z 681.31, 817.89 and 
1076.40 were observed in the modified creatine kinase B-type digest chromatogram but not 
in the analysis  of the unmodified creatine kinase B-type digest. Ions at these m/z values 
were therefore fragmented by CID to obtain product ion spectra (Figure 7.11). The spectra 
provided sufficient information to identify both the peptide sequence and the site of 
modification: E41, E362 and C283 were modified by AB-(R)-lacosamide analogue B. Protein 
data bank provides a crystal structure of the human brain-type creatine kinase expressed 
from E.coli containing two monomers126. E41, E362 and C283 were mapped to the crystal 
structure (Figure 7.12). E41 and E362 are on the surface. It is possible that modification of 
these residues arises due to their ease of accessibility by analogue B. C283 is in the 
catalytic site of the protein and not on the surface of the protein128. The modification of the 
catalytic site increases the interest in this candidate target and pharmaceutical studies are in 
progress in collaborator laboratories to confirm this candidate. 
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Figure 7.10 ESI-QToF deconvoluted mass spectra of the unmodified creatine kinase B-type (A), 5 μM (B),  50 μM (C), 500 μM (D) and 5mM (E) 
modified creatine kinase B-type by (R)-lacosamide analogue B. M, M*, M**and M*** refer to unmodified, mono-adducted, di-adducted and tri-adducted  
creatine kinase B-type, respectively.
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Figure 7.11 Product ion spectra of modified creatine kinase B type peptides (A) product ion spectrum of doubly protonated modified LLIEMEQR at m/z 
681.31, (B) product ion spectrum of doubly protonated modified VLTPELYAELR at m/z 817.89, (C) product ion spectrum of triply protonated modified 
NYEFMWNPHLGYILTCPSNLGTGLR at m/z 1076.40. [M+3H]3+ refers to triply protonated modified peptide, b* and y* refer to fragment ions containing the 
biotinyl (R)-lacosamide analogue C. 
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Figure 7.12 3D-model of the quaternary structure of creatine kinase B-type consist of 
two monomers. E41 and E362 are on the surface modified by (R)-lacosamide analogue B. 
C283 is catalytic site also modified by (R)-lacosamide analogue B.  
 
7.5 Discussion 
 
 Methods were developed to enrich peptides containing biotinyl (R)-lacosamide 
analogue A using streptavidin beads. Using biotin in the elution buffer is an effective method 
to elute biotinylated peptides from the avidin beads as the excess biotin in the elution buffer 
displaces the biotinylated peptides from the streptavidin beads. This method is more 
selective to elute biotinylated peptides than other methods which are based on denaturing 
the streptavidin structure to elute all peptides including non-selective binding peptides.  
Subsequent analysis of the biotinylated peptides using CID and ETD fragmentation methods 
demonstrated that neither technique was optimal to determine the sequence or site of 
modification of unknown peptides. CID tandem mass spectra provided sequence related ion 
signals in very low intensities. ETD tandem mass spectrometry yielded only a few sequence 
related fragment ions which were generally insufficient to determine the sequence of 
unknown peptides. For future work, the ETD analysis still needs more optimization before 
applying to use for whole lysate experiments. To identify modification sites in this thesis, 
purified proteins (previously identified as candidate targets) were adducted with only AB-(R)-
lacosamide analogue without biotin probe, used instead of the biotinyl (R)-lacosamide 
analogue. This smaller (R)-lacosamide analogue underwent less fragmentation than the 
biotin analogue during CID and could be used for sequence and site identification. Using this 
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method, K120 was identified as the modification site of AB-(R)-lacosamide analogue A on 
14-3-3 zeta protein. The isothiocyanate could react with the lysine at a low amount of 
analogue A, 10 fold μM excess. Moreover, this residue is not on the surface of protein, but in 
a functional area of the 14-3-3 protein124. K472 of CRMP2 was found to be modified. K472 
has not been implicated in specific protein functions, but it is in a region that is very close to 
areas implicated in binding to calcium channels (479-500)126, calmodulin (475-493), and 
GAP activity for stimulating tubulin GTP hydrolysis (480-509)127. The modification of residue 
nearby the functional site increases the interest in this candidate target. E41, E362 and C283 
of creatine kinase B type were found to be modified by AB-(R)-lacosamide analogue B. The 
expoxy group normally reacts with a nucleophilic amino acid, such as cysteine. It is also 
possible to bind with glutamic acid129.  E41 and E362 are on the surface, suggesting that 
their modification maybe attributable to ease of access by analogue B. C283 is the catalytic 
site of the protein and not on the surface of the protein128. 14-3-3 zeta protein and creatine 
kinase B-type provide interesting evidence to be potential targets of (R)-lacosamide.  The 
pharmaceutical studies are in progress in the collaborator’s laboratories to confirm this 
finding.
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CHAPTER 8 
Summary and Conclusions 
 
The aim of the work presented in this thesis was to develop techniques for the 
identification of target proteins of (R)-lacosamide. Here, the strategy for enriching target 
proteins from mouse brain lysate was ligand-based affinity purification. The lacosamide 
molecule is modified with two functional groups, an ‘affinity bait’ (AB) and a ‘chemical 
reporter’ (CR). The affinity bait binds covalently with amino acid residues in the target 
protein. The chemical reporter react with a biotin (or fluorescent) probe which can then be 
used for (visualisation or) subsequent streptavidin affinity purification of bound target 
proteins.  
Mass spectrometric characterisation of the biotinyl (R)-lacosamide analogue A 
bound to model compounds was studied in Chapter 3. Neither protonated modified protein 
nor modified peptide, in the tryptic digest, could  be observed using MALDI; this was 
attributed to the transfer of excess energy  to the analyte resulting in its decomposition and 
loss of the modification prior to mass analysis. ESI is therefore more suitable to use in the 
analysis of lacosamide analogue modified peptides and proteins.  However, during CID, the 
analogue A preferentially cleaves from the peptide and it is not possible to identify the 
modification site directly. Prediction of the site of modification can be done by observation of 
the presence and localization of lysine and cysteine residues in the sequence. 
 Chapters 4 and 6 describe the ligand-based affinity purification strategy using the 
(R)-lacosamide analogues A, B, C and D to isolate target proteins from mouse and rat brain 
lysate. Analogue A identified the most potential target proteins, with the other analogues 
supporting the findings. Only keratin was observed from the negative control experiment (a 
common contaminant found in many MS experiments arising from sample handling). The on-
bead digestion protocol coupled with SCX separation of peptides prior to LC-MS/MS 
increased the capability of detecting candidate target proteins.  Chapter 5 describes the 
increase in the relative amounts of each tryptic fragment from the (R)-lacosamide analogue 
A treated sample compared with (S)-lacosamide analogue A. These studies were important 
because whole animal pharmacological studies have demonstrated that the anticonvulsant 
activity is primarily confined to the (R)-stereoisomer. The 14-3-3 protein family, CRMP2 and 
the sodium/potassium-transporting ATPase family all demonstrated this preference. As the 
biotin analogue could not be used successfully to define the site of modification of the 
enriched peptides, purified recombinant proteins (previously identified as candidate targets) 
were adducted with the AB-(R)-lacosamide analogue lacking the biotin probe, instead of the 
biotinyl (R)-lacosamide analogue. These studies, described in Chapter 7, demonstrated that 
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this smaller (R)-lacosamide analogue underwent less fragmentation that the biotin analogue 
during CID and could be used for sequence and site identification. 
 Some of the identified proteins are housekeeping proteins, which are of high 
abundance in the cell: for example actin and glyceraldehyde-3-phosphate dehydrogenase107. 
Because of their abundance in lysate, their presence in the enriched fraction might be 
attributable solely to non-selective binding to streptavidin, and their observation is 
accordingly of lesser interest.  However, there are at least four candidate proteins that are 
potentially very interesting. Firstly, dihydropyrimidinase-related protein  is  present in low 
abundance in brain cells 108 but it was shown as a high abundance protein after enriching by 
analogue A and C. It also showed preferential binding to (R)- rather  than (S)-lacosamide 
analogues in several studies. Moreover, the progress report on new antiepileptic drugs, at 
the Ninth Eilat Conference, suggests that lacosamide has a novel mechanism of action and 
functions by modulating the activity of CRMP2112. K472 has not been implicated in specific 
protein functions, but it is in a region that is very close to areas implicated in binding to 
calcium channels (479-500)126, calmodulin (475-493), and GAP activity for stimulating tubulin 
GTP hydrolysis (480-509)127. The modification of residue nearby the functional site increases 
the interest in this candidate target. Secondly, the 14-3-3 protein family was enriched by 
analogues A and C. They also showed preference for the (R)- rather than the (S)-lacosamide 
analogue. Moreover, K120 was identified as the modification site of AB-(R)-lacosamide 
analogue A on 14-3-3 zeta protein. Crystal structure analysis reveals that this residue is not 
on the surface of protein, but is likely to be in a functional area of the 14-3-3 isoform124. This 
protein is also reported to be involved in epilepsy; examination of the levels of 14-3-3 
proteins in the cerebrospinal fluid of rats post-seizure demonstrated a significant increase. 
Specifically, 14-3-3 zeta was detected at significant levels increase as 6-fold in cerebrospinal 
fluid sampled 4 hours after seizure, suggesting that the presence of 14-3-3 zeta within 
cerebrospinal fluid may be a biomarker of acute seizure damage111. Thirdly, the 
sodium/potassium-transporting ATPase family were enriched by analogues A and C. They 
also showed preference for the (R)- rather than the (S)-lacosamide analogue. This protein 
has also been reported to be involved in epilepsy. The sodium/potassium-transporting 
ATPase catalytic subunit had a decreased affinity for K+ in the human epileptic cortex113. 
Changing of K+ regulation could be responsible for seizure spread. Finally, creatine kinase 
B-type was identified using analogues A, B and C. E41, E362 and C283 of creatine kinase B 
type were found to be modified by AB-(R)-lacosamide analogue B.  E41 and E362 are on the 
surface. Modification of these sites may therefore arise due to the ease of accessibility for 
analogue B. However, C283 is in the catalytic site of the protein and not on the surface128.  
This protein has been reported to be involved in seizure. Seizure patients’ serum levels of 
creatine kinase drawn at the fourth hour of the seizure were significantly higher than baseline 
levels; serum creatine kinase measurements are reported to be a potentially useful 
laboratory test to differentiate tonic-clonic seizures  from  syncope (loss of consciousness 
resulting from insufficient blood flow to the brain)116. 
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In summary, the studies illustrated the power of MS to discover candidate protein 
targets.  It is also possible to define the binding sites of the drug analogue to the target 
proteins. However, all of the candidate target proteins need to be further validated using 
pharmacology studies in order to understand the mechanism(s) of action of this novel anti-
epileptic therapeutic. 
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